Track market-moving stories before they get noisy

Injective is now processing blocks in 0.59 seconds. For a layer-1 blockchain built specifically for financial applications, that’s the kind of speed that turns heads, particularly among traders who lose money every millisecond a transaction sits in limbo.

The milestone, reported on July 30, 2026, follows a mainnet upgrade dubbed IIP-665/v1.20.1 that pushed block times consistently below the 0.6-second threshold.

A year of incremental speed gains Back in November 2025, the network launched its native EVM mainnet with block times of 0.64 seconds. Then came the April 28, 2026 upgrade, version 1.19.0, which cut block finality from 1.2 seconds down to 0.7 seconds. That’s a 42% reduction in a single update.

Advertisement

The latest upgrade also earned backing from major exchanges, with Binance among those supporting the transition.

Why sub-second finality matters for finance Derivatives trading, the core use case Injective has been targeting since its inception, operates on razor-thin margins where execution speed directly impacts profitability.

The network has now processed over 3 billion on-chain transactions since its launch.

Asset tokenization is the other pillar of Injective’s strategy. As more real-world assets move on-chain, from treasuries to commodities to equities, the settlement layer underneath needs to be fast enough that tokenized trading doesn’t feel like a downgrade from traditional rails.

The competitive landscape is heating up Solana, the most prominent speed-focused chain, has historically advertised 400-millisecond block times, though its actual performance has varied due to network congestion and outage episodes.

The Cosmos SDK underpinning, combined with Injective’s custom consensus modifications, gives the network a different architectural path than its EVM-native or Move-based competitors. The native EVM compatibility added in November 2025 was a strategic move to capture Ethereum’s developer ecosystem without sacrificing the performance advantages of the underlying Tendermint-derived consensus.

The risk, as always with performance-focused upgrades, is that speed gains come at the cost of decentralization or security. Investors should monitor validator counts and distribution post-upgrade to ensure the network isn’t achieving its speed targets by quietly concentrating power among fewer, more powerful nodes.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.

Carpenter Technology Corporation (CRS) Q4 2026 Earnings Call July 30, 2026 10:00 AM EDT

Company Participants

John Huyette - VP of Corporate Development & Investor Relations
Tony Thene - President, CEO & Chairman of the Board
Timothy Lain - Senior VP & CFO

Conference Call Participants

Scott Deuschle - Deutsche Bank AG, Research Division
Gautam Khanna - TD Cowen, Research Division
David Strauss - Wells Fargo Securities, LLC, Research Division
Bennett Moore - JPMorgan Chase & Co, Research Division
Joshua Sullivan - JonesTrading Institutional Services, LLC, Research Division
Andre Madrid - BTIG, LLC, Research Division

Presentation

Operator

Hello, everyone, and thank you for joining us, and welcome to the Carpenter Technology Corp Q4 FY '26 Earnings Presentation. [Operator Instructions] I will now hand the conference over to John Huyette, Vice President, Investor Relations. Please go ahead.

John Huyette
VP of Corporate Development & Investor Relations

Thank you, operator. Good morning, everyone, and welcome to the Carpenter Technology Earnings Conference Call for the fiscal 2026 Fourth Quarter ended June 30, 2026. This call is also being broadcast over the Internet along with presentation slides. For those of you listening by phone, you may experience a time delay in slide movement. Speakers on the call today are Tony Thene, Chairman, President and Chief Executive Officer; and Tim Lain, Senior Vice President and Chief Financial Officer. Statements made by management during this earnings presentation that are forward-looking statements are based on current expectations.

Risk factors that could cause actual results to differ materially from these forward-looking statements can be found in Carpenter Technology's most recent SEC filings, including the company's report on Form 10-K for the year ended June 30, 2025, Forms 10-Q for the quarters ended September 30, 2025, December 31, 2025, and March 31, 2026, and the exhibits attached to those filings.

Please also note that

Huntington Ingalls Industries, Inc. (HII) Q2 2026 Earnings Call July 30, 2026 9:00 AM EDT

Company Participants

Christie Thomas - Vice President of Investor Relations
Christopher Kastner - President, CEO & Director
Brian Blanchette - Executive VP & President of Ingalls Shipbuilding Division
Thomas Stiehle - Executive VP & CFO

Conference Call Participants

John Godyn - Citigroup Inc., Research Division
Noah Poponak - Goldman Sachs Group, Inc., Research Division
Scott Mikus - Melius Research LLC
Gautam Khanna - TD Cowen, Research Division
Douglas Harned - Bernstein Institutional Services LLC, Research Division
Scott Deuschle - Deutsche Bank AG, Research Division
Benjamin Tomick - Wells Fargo Securities, LLC, Research Division
Ronald Epstein - BofA Securities, Research Division
Emilee Deutchman - Wolfe Research, LLC
Seth Seifman - JPMorgan Chase & Co, Research Division

Presentation

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Second Quarter 2026 HII Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]

I would now like to hand the call over to Christie Thomas, Vice President of Investor Relations. Mrs. Thomas, you may begin.

Christie Thomas
Vice President of Investor Relations

Thank you, operator, and good morning, everyone. Welcome to the HII Second Quarter 2026 Conference Call. .

Matters discussed on today's call that constitute forward-looking statements, including our estimates regarding the company's outlook, involve risks and uncertainties and reflect the company's judgment based on information available at the time of this call. These risks and uncertainties may cause our actual results to differ materially. Additional information regarding these factors is contained in today's press release and the company's SEC filings.

We will also refer to certain non-GAAP financial measures. For additional disclosures about these non-GAAP measures, including reconciliations to comparable GAAP measures, please see the slides that accompany this webcast, which are available on the Investor Relations page of our website

HomeEarnings AnalysisEnergy Analysis

SummaryEnterprise Products Partners L.P. delivered a record Q2, with revenues 30% above estimates and distributable cash flow up 21% year-over-year.EPD's robust results stem from macro tailwinds, AI-driven energy demand, and recent growth investments, including new LNG export capacity.With a strong 1.9x dividend coverage ratio and moderating growth CapEx ahead, EPD appears poised for accelerated dividend growth.Despite recent price appreciation, EPD stock remains attractive for income-focused investors seeking potential double-digit total returns.Looking for a helping hand in the market? Members of Cash Flow Club get exclusive ideas and guidance to navigate any climate. Learn More » Richard Drury/DigitalVision via Getty Images

Article Thesis Enterprise Products Partners L.P. (EPD) announced its Q2 earnings results on Thursday. The record quarter shows that the combination of macro tailwinds and EPD's growth investments is working out very well

54.25K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of EPD, ET, MPLX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Second quarter 2026 revenue and Adjusted EBITDA exceed high end of guidance range 
Company provides updated full year 2026 guidance following recently completed divestiture

MINNEAPOLIS, July 30, 2026 (GLOBE NEWSWIRE) -- SPS Commerce, Inc. (NASDAQ: SPSC), the leading intelligent supply chain network, today announced financial results for the second quarter ended June 30, 2026.

Financial Highlights

Second Quarter 2026 Financial Highlights

Revenue was $197.8 million in the second quarter of 2026, compared to $187.4 million in the second quarter of 2025, reflecting 6% growth.Recurring revenue grew 6% from the second quarter of 2025.Net income was $6.9 million or $0.19 per diluted share, compared to net income of $19.7 million or $0.52 per diluted share in the second quarter of 2025.Non-GAAP income was $46.4 million or $1.27 per diluted share, compared to non-GAAP income of $38.0 million or $1.00 per diluted share in the second quarter of 2025.Adjusted EBITDA for the second quarter of 2026 increased 19% to $66.6 million compared to the second quarter of 2025.Share repurchases in the second quarter of 2026 totaled $51.2 million. “SPS Commerce is executing its growth and innovation roadmap. MAX, our agentic capabilities embedded within SPS' supply chain network, has already delivered tangible value to beta users, equating to hundreds of thousands of dollars in savings to individual customers in just a matter of three months. We are excited about MAX’s launch to all SPS Fulfillment customers later this summer,” said Chad Collins, CEO of SPS Commerce. “No other company can match the unique combination of AI capabilities, 25 years of proprietary data, deep domain expertise, and expansive network access to drive this kind of tangible value, collaboration, and operational efficiencies that SPS offers today.”

“Solid second-quarter performance reflects up-sell and cross-sell momentum across our core business,” said Joe Del Preto, CFO of SPS Commerce. “We continue to demonstrate operational rigor, exceeding our margin expansion goals while simultaneously rolling out our AI strategy across the SPS network.” 

Guidance

As a result of the divestiture of the 3P Revenue Recovery business on June 30, 2026, guidance factors in a reduction of approximately $10.5 million in revenue to the second half of 2026. The divestiture is expected to be neutral to Adjusted EBITDA in the second half of 2026.

Third Quarter 2026 Guidance

Revenue is expected to be in the range of $196.3 million to $198.3 million.Net income per diluted share is expected to be in the range of $0.72 to $0.76, with fully diluted weighted average shares outstanding of 36.8 million shares.Non-GAAP income per diluted share is expected to be in the range of $1.20 to $1.23.Adjusted EBITDA is expected to be in the range of $67.4 million to $69.4 million.Non-cash, share-based compensation expense is expected to be $16.4 million, depreciation expense is expected to be $5.4 million, and amortization expense is expected to be $8.5 million. Fiscal Year 2026 Guidance

Revenue is expected to be in the range of $788.4 million to $793.4 million, representing 5% to 6% growth over 2025.Net income per diluted share is expected to be in the range of $2.24 to $2.33, with fully diluted weighted average shares outstanding of 36.9 million shares.Non-GAAP income per diluted share is expected to be in the range of $4.84 to $4.93.Adjusted EBITDA is expected to be in the range of $264.6 million to $269.1 million, reflecting an Adjusted EBITDA margin of 34% at the midpoint, an increase of approximately 300 basis points compared to full year 2025.Non-cash, share-based compensation expense is expected to be $69.8 million, depreciation expense is expected to be $23.4 million, and amortization expense is expected to be $35.6 million. The forward-looking measures and the underlying assumptions involve significant known and unknown risks and uncertainties, and actual results may vary materially. The Company does not present a reconciliation of the forward-looking non-GAAP financial measures, including Adjusted EBITDA, Adjusted EBITDA margin, and non-GAAP income per share, to the most directly comparable GAAP financial measures because it is impractical to forecast certain items without unreasonable efforts due to the uncertainty and inherent difficulty of predicting, within a reasonable range, the occurrence and financial impact of and the periods in which such items may be recognized.

Quarterly Conference Call
To access the call, please dial 1-833-816-1382, or outside the U.S. 1-412-317-0475 at least 15 minutes prior to the 3:30 p.m. CT start time. Please ask to join the SPS Commerce Q2 2026 conference call. A live webcast of the call will also be available at http://investors.spscommerce.com under the Events and Presentations menu. The replay will also be available on our website at http://investors.spscommerce.com.

About SPS Commerce
SPS Commerce (NASDAQ: SPSC) is the leading intelligent supply chain network, connecting trading partners around the globe to optimize supply chain operations with all retail partners. Our AI-powered network connects 300,000+ trading relationships worldwide and moves more than 750M transactions and over $650B in gross merchandise value each year. From retailers and brands to manufacturers, distributors, and logistics providers, SPS is trusted by seven of the top ten largest retailers, and over two-thirds of today’s fastest growing brands. Our multi-solution portfolio orchestrates the data, decisions, and relationships that keep the world's supply chains moving forward. With nearly 3,000 employees and global offices, SPS Commerce is headquartered in Minneapolis, Minnesota. For more information, visit spscommerce.com.

SPS COMMERCE, SPS, SPS logo and INFINITE RETAIL POWER are marks of SPS Commerce, Inc. and registered in the U.S. Patent and Trademark Office, along with other SPS marks. Such marks may also be registered or otherwise protected in other countries. 

SPS-F

Use of Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, we provide investors with Adjusted EBITDA, Adjusted EBITDA Margin, and non-GAAP income per share, all of which are non-GAAP financial measures. We believe that these non-GAAP financial measures provide useful information to our management, Board of Directors, and investors regarding certain financial and business trends relating to our financial condition and results of operations.

Our management uses these non-GAAP financial measures to compare our performance to that of prior periods for trend analyses and planning purposes. Adjusted EBITDA is also used for purposes of determining executive and senior management incentive compensation. We believe these non-GAAP financial measures are useful to an investor as they are widely used in evaluating operating performance. Adjusted EBITDA and Adjusted EBITDA Margin are used to measure operating performance without regard to items such as depreciation and amortization, which can vary depending upon accounting methods and the book value of assets, and to present a meaningful measure of corporate performance exclusive of capital structure and the method by which assets were acquired.

These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP. These non-GAAP financial measures exclude significant expenses and income that are required by GAAP to be recorded in our condensed consolidated financial statements and are subject to inherent limitations. Investors should review the reconciliations of non-GAAP financial measures to the comparable GAAP financial measures that are included in this press release.

Adjusted EBITDA Measures:

Adjusted EBITDA consists of net income adjusted for income tax expense, depreciation and amortization expense, stock-based compensation expense, realized gain from investments and foreign currency transactions, investment income, loss on sale of business, and other adjustments as necessary for a fair presentation. Other adjustments for the three and six months ended June 30, 2026, included the expense impact from disposals of other equipment, remeasurement of an acquired earn-out liability, and one-time divestiture exit and disposal costs. Net income is the most directly comparable GAAP measure of financial performance.

Adjusted EBITDA Margin consists of Adjusted EBITDA divided by revenue. Margin, the comparable GAAP measure of financial performance, consists of net income divided by revenue.

Non-GAAP Income Per Share Measure:

Non-GAAP income per share consists of net income adjusted for stock-based compensation expense, amortization expense related to intangible assets, realized gain from investments and foreign currency transactions, loss on sale of business, and other adjustments as necessary for a fair presentation, including for the three and six months ended June 30, 2026, the expense impact from disposals of other equipment, remeasurement of an acquired earn-out liability, and one-time divestiture exit and disposal costs, and the corresponding tax impacts of the adjustments to net income, divided by the weighted average number of shares of common and diluted stock outstanding during each period. Net income per share, the most directly comparable GAAP measure of financial performance, consists of net income divided by the weighted average number of shares of common and diluted stock outstanding during each period. To quantify the tax effects, we recalculated income tax expense excluding the direct book and tax effects of the specific items constituting the non-GAAP adjustments. The difference between this recalculated income tax expense and GAAP income tax expense is presented as the income tax effect of the non-GAAP adjustments.

Forward-Looking Statements

This press release may contain forward-looking statements, including information about management's view of SPS Commerce's future expectations, plans and prospects, including our views regarding future execution within our business, the opportunity we see in the retail supply chain world and our performance for the third quarter and full year of 2026, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results of SPS Commerce to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are included in documents SPS Commerce files with the Securities and Exchange Commission, including but not limited to, SPS Commerce's Annual Report on Form 10-K for the year ended December 31, 2025, as well as subsequent reports filed with the Securities and Exchange Commission. Other unknown or unpredictable factors also could have material adverse effects on SPS Commerce's future results. The forward-looking statements included in this press release are made only as of the date hereof. SPS Commerce cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, SPS Commerce expressly disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

SPS COMMERCE, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited; In thousands, except shares)  June 30,
2026 December 31,
2025ASSETS   Current assets   Cash and cash equivalents$173,167  $151,355 Accounts receivable 71,681   75,295 Allowance for credit losses (7,994)  (7,129)Accounts receivable, net 63,687   68,166 Deferred costs 64,001   66,693 Other assets 29,541   49,090 Total current assets 330,396   335,304 Property and equipment, net 44,142   43,117 Operating lease right-of-use assets 4,985   5,025 Goodwill 539,411   541,719 Intangible assets, net 172,446   215,815 Other assets   Deferred costs, non-current 20,296   20,719 Deferred income tax assets 514   493 Other assets, non-current 13,239   7,667 Total assets$1,125,429  $1,169,859 LIABILITIES AND STOCKHOLDERS’ EQUITY   Current liabilities   Accounts payable$9,484  $13,757 Accrued compensation 39,470   47,577 Accrued expenses 14,901   13,074 Deferred revenue 80,867   75,590 Operating lease liabilities 1,540   4,353 Total current liabilities 146,262   154,351 Other liabilities   Deferred revenue, non-current 4,720   5,288 Operating lease liabilities, non-current 4,766   2,839 Deferred income tax liabilities 30,928   33,201 Other liabilities, non-current 271   287 Total liabilities 186,947   195,966 Commitments and contingencies   Stockholders' equity   Common stock 40   40 Treasury stock (276,922)  (177,949)Additional paid-in capital 763,354   722,737 Retained earnings 456,031   429,438 Accumulated other comprehensive loss (4,021)  (373)Total stockholders’ equity 938,482   973,893 Total liabilities and stockholders’ equity$1,125,429  $1,169,859  SPS COMMERCE, INC.
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited; in thousands, except per share amounts)  Three Months Ended
June 30, Six Months Ended
June 30, 2026
 2025
 2026
 2025
Revenues$197,815 $187,400 $389,936 $368,949Cost of revenues 59,028  59,826  118,245  116,740Gross profit 138,787  127,574  271,691  252,209Operating expenses       Sales and marketing 43,936  43,434  88,670  85,068Research and development 16,957  17,271  34,874  34,710General and administrative 36,646  30,890  73,020  61,908Amortization of intangible assets 9,381  9,509  18,701  18,097Loss on sale of business 23,454  —  23,454  —Total operating expenses 130,374  101,104  238,719  199,783Income from operations 8,413  26,470  32,972  52,426Other income, net 1,997  773  3,402  2,980Income before income taxes 10,410  27,243  36,374  55,406Income tax expense 3,546  7,510  9,781  13,477Net income$6,864 $19,733 $26,593 $41,929        Net income per share       Basic$0.19 $0.52 $0.72 $1.10Diluted$0.19 $0.52 $0.72 $1.10        Weighted average common shares used to compute net income per share       Basic 36,533  37,965  36,953  37,978Diluted 36,577  38,099  37,026  38,132         SPS COMMERCE, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; in thousands)
  Six Months Ended
June 30, 2026
 2025
Cash flows from operating activities   Net income$26,593  $41,929 Reconciliation of net income to net cash provided by operating activities   Deferred income taxes (4,412)  (5,914)Depreciation and amortization of property and equipment 11,984   9,948 Amortization of intangible assets 18,701   18,097 Provision for credit losses 4,621   4,111 Stock-based compensation 36,769   28,865 Loss on sale of business 23,454   — Other, net (1,445)  274 Changes in assets and liabilities, net of effects of acquisitions   Accounts receivable (2,139)  (13,713)Deferred costs 2,797   (412)Other assets and liabilities 11,871   (2,258)Accounts payable (3,236)  2,082 Accrued compensation (9,551)  (11,006)Accrued expenses 1,419   (1,833)Deferred revenue 5,087   3,012 Operating leases (854)  (876)Net cash provided by operating activities 121,659   72,306 Cash flows from investing activities   Purchases of property and equipment (15,738)  (12,815)Proceeds from sale, net 8,768   — Acquisition of business, net —   (142,628)Net cash used in investing activities (6,970)  (155,443)Cash flows from financing activities   Repurchases of common stock (98,358)  (59,558)Net proceeds from exercise of options to purchase common stock 866   2,406 Net proceeds from employee stock purchase plan activity 4,321   5,426 Net cash used in financing activities (93,171)  (51,726)Effect of foreign currency exchange rate changes 294   1,449 Net increase (decrease) in cash and cash equivalents 21,812   (133,414)Cash and cash equivalents at beginning of period 151,355   241,017 Cash and cash equivalents at end of period$173,167  $107,603  SPS COMMERCE, INC.
NON-GAAP RECONCILIATIONS
(Unaudited; in thousands, except Margin, Adjusted EBITDA Margin, and per share amounts)
 Adjusted EBITDA  Three Months Ended
June 30, Six Months Ended
June 30, 2026
 2025
 2026
 2025
Net income$6,864  $19,733  $26,593  $41,929 Income tax expense 3,546   7,510   9,781   13,477 Depreciation and amortization of property and equipment 6,150   4,991   11,984   9,948 Amortization of intangible assets 9,381   9,509   18,701   18,097 Stock-based compensation expense 18,696   14,998   36,769   28,865 Realized gain from investments and foreign currency transactions (402)  (107)  (522)  (473)Investment income (1,211)  (688)  (2,362)  (2,537)Loss on sale of business 23,454   —   23,454   — Other 154   106   165   1,119 Adjusted EBITDA$66,632  $56,052  $124,563  $110,425  Adjusted EBITDA Margin
  Three Months Ended
June 30, Six Months Ended
June 30, 2026
 2025
 2026
 2025
Revenue$197,815  $187,400  $389,936  $368,949         Net income 6,864   19,733   26,593   41,929 Margin 3%  11%  7%  11%        Adjusted EBITDA 66,632   56,052   124,563   110,425 Adjusted EBITDA Margin 34%  30%  32%  30% Non-GAAP Income per Share  Three Months Ended
June 30, Six Months Ended
June 30, 2026
 2025
 2026
 2025
Net income$6,864  $19,733  $26,593  $41,929 Stock-based compensation expense 18,696   14,998   36,769   28,865 Amortization of intangible assets 9,381   9,509   18,701   18,097 Realized gain from investments and foreign currency transactions (402)  (107)  (522)  (473)Loss on sale of business 23,454   —   23,454   — Other 154   106   165   1,119 Income tax effects of adjustments (11,770)  (6,285)  (17,649)  (13,570)Non-GAAP income$46,377  $37,954  $87,511  $75,967         Shares used to compute net income and non-GAAP income per share       Basic 36,533   37,965   36,953   37,978 Diluted 36,577   38,099   37,026   38,132         Net income per share, basic$0.19  $0.52  $0.72  $1.10 Non-GAAP adjustments to net income per share, basic 1.08   0.48   1.65   0.90 Non-GAAP income per share, basic$1.27  $1.00  $2.37  $2.00         Net income per share, diluted$0.19  $0.52  $0.72  $1.10 Non-GAAP adjustments to net income per share, diluted 1.08   0.48   1.65   0.89 Non-GAAP income per share, diluted$1.27  $1.00  $2.36  $1.99 
The annual per share amounts may not cross-sum due to rounding.

Contact:
Investor Relations
The Blueshirt Group
Irmina Blaszczyk
[email protected]

MarketBeat Week in Review – 02/17 - 02/21Kyndryl NYSE: KD shareholders approved all four proposals at the company’s 2026 annual meeting, including the election of six director nominees, an advisory vote on executive compensation, an amended and restated long-term performance plan, and the appointment of PricewaterhouseCoopers as independent auditor for fiscal 2027.

Chairman and Chief Executive Officer Martin Schroeter said preliminary voting results showed that each director nominee was elected for a one-year term. Shareholders also approved the company’s executive-compensation proposal and the amended and restated Kyndryl 2021 Long-Term Performance Plan. The company’s ratification of PricewaterhouseCoopers as its independent registered public accounting firm for the fiscal year ending March 31, 2027, also passed.

Get Kyndryl alerts:

Kyndryl Soars on AI, Cybersecurity Growth—What’s Next?Kyndryl said 220.5 million common shares were outstanding and eligible to vote as of the June 3 record date. A quorum was present at the virtual meeting, according to the company’s inspector of election.

Executive compensation vote Schroeter addressed shareholder questions concerning executive compensation, the company’s stock price and financial performance before the votes were tabulated. He said Kyndryl’s compensation structure is intended to be pay-for-performance, with approximately 60% of target compensation for named executive officers tied to performance measures.

MarketBeat Week in Review – 9/25 - 9/29Between 70% and 95% of compensation for named executives is variable and at risk, he said. The Compensation and Human Capital Committee established fiscal 2026 targets at the beginning of the year, with input from an independent compensation consultant, and did not revise them during the year.

The committee set an adjusted EBITDA target more than 9% above the company’s fiscal 2025 result, Schroeter said. Although adjusted EBITDA increased year over year in fiscal 2026, annual bonuses were paid at 69% of target, down from 118% in the prior year. He said no discretionary adjustments were made.

Schroeter also said the realizable value of equity awards granted to named executive officers had fallen substantially from their original grant values, reflecting company performance and stock-price movement during the year.

Strategy focused on higher-value services and AI In his company report following the formal meeting, Schroeter characterized fiscal 2026 as a year of continued progress, highlighting Kyndryl’s “three As” strategy: Alliances, Advanced Delivery and Accounts.

The company is continuing to invest in Kyndryl Consult, its technology-alliance partnerships and artificial-intelligence capabilities. Schroeter said Kyndryl Consult delivered another year of strong revenue growth as organizations sought advisory, modernization and implementation services.

Kyndryl’s expanding alliances ecosystem is intended to help customers advance cloud, data and AI initiatives, he said. The company is also using its AI-powered Kyndryl Bridge platform and emerging agentic AI capabilities to help customers modernize IT infrastructure, improve resiliency and scale AI deployments.

Schroeter said enterprises face a modernization challenge because many technology environments were not designed for AI demands, heightened cybersecurity requirements or increasingly complex operations. He said Kyndryl’s ability to operate and modernize mission-critical systems simultaneously, while maintaining continuity and reducing operational risk, positions the company to support enterprise transformation.

Kyndryl Bridge provides visibility, operational intelligence and governance across complex technology estates, Schroeter said. Combined with Kyndryl’s engineering expertise and technology alliances, the platform is intended to continuously modernize IT environments and prepare them for AI at scale.

Leadership changes and control remediation Schroeter said Andrew Bonzani joined Kyndryl as general counsel and secretary on July 6. Ellen Johnson is scheduled to assume the chief financial officer role on Aug. 6, following the filing of the company’s first-quarter earnings and Form 10-Q.

He thanked interim CFO Harsh Chugh and interim General Counsel Mark Ringes for leading the finance and legal organizations during the transition. Schroeter said Bonzani and Johnson bring experience in financial discipline, operational excellence and governance at global public companies.

The company is also taking actions to enhance its controls and execute its material-weakness remediation plan. Schroeter said Kyndryl is aiming to remediate its previously disclosed material weaknesses as of March 31, 2027.

Schroeter said the IT-services sector, including Kyndryl, has faced pressure over the past year as AI has created both opportunities and uncertainty across technology markets. He said Kyndryl views AI as a growth opportunity, citing its experience managing complex IT estates, investments in Kyndryl Bridge and relationships with hyperscalers and other technology companies.

“Ultimately, our focus remains on disciplined execution, delivering for our customers, and building sustainable long-term value for our shareholders,” Schroeter said.

About Kyndryl (NYSE:KD)Kyndryl NYSE: KD is a global managed infrastructure services provider formed in November 2021 through the spin-off of IBM's Managed Infrastructure Services business. The company designs, builds, manages and modernizes critical information technology systems for enterprises worldwide. Kyndryl's core offerings include cloud migration and management, network and edge computing solutions, digital workplace services and IT resiliency and security capabilities.

With a workforce of approximately 90,000 professionals and operations in more than 60 countries, Kyndryl serves clients across a broad range of industries, including financial services, telecommunications, healthcare, manufacturing and retail.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Kyndryl Right Now?Before you consider Kyndryl, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kyndryl wasn't on the list.

While Kyndryl currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Key Takeaways Littelfuse highlighted data center growth, industrial recovery and strategic progress in Q2.LFUS reported Q2 revenue growth of 20% year over year, with organic growth of 14%.LFUS expects Q3 revenues of $780M-$800M, with Basler contributions supporting growth. Littelfuse, Inc. (LFUS - Free Report) highlighted broad-based demand strength and strategic progress during its second-quarter 2026 earnings call, with management emphasizing data center growth, industrial recovery and customer design wins as key drivers.

Executives also raised their outlook for the next quarter, citing record bookings, stronger customer momentum and contributions from the Basler acquisition.

LFUS Data Center MomentumManagement identified data center demand as one of the strongest growth drivers during the quarter. Chief executive officer Gregory Henderson said growth in computing, communications and diversified industrial markets was supported by Littelfuse’s ability to provide solutions across electrical architectures.

Henderson noted that current data center revenue growth is primarily tied to lower-voltage architectures, while future opportunities are expected from higher-voltage systems. He said design wins related to these next-generation architectures increased significantly during the first half of 2026.

Chief financial officer Abhishek Khandelwal added that higher-voltage architectures represent a larger content opportunity compared with existing solutions. Management reiterated confidence in its long-term data center growth framework during the call.

Littelfuse Sees Broader DemandLittelfuse reported second-quarter adjusted earnings per share of $4.19 and revenues of $738.8 million, exceeding the Zacks Consensus Estimate of $3.77 and $701 million, respectively. The company reported revenue growth of 20% year over year, with organic growth of 14%.

Henderson emphasized that growth was becoming more balanced across end markets rather than being concentrated in a few areas. He pointed to diversified industrial demand, including medical and aerospace and defense markets, as contributors to momentum.

The company also highlighted improving industrial conditions, including stronger demand in industrial automation, construction and HVAC. Management said HVAC recovery was faster than previously expected, supporting industrial performance.

LFUS Industrial ExpansionThe Industrial segment was a major contributor to quarterly growth, with sales increasing 52% year over year. Organic growth was 16%, supported by data center, industrial automation and construction demand, while the Basler acquisition contributed 36% of segment growth.

Management said Basler integration was progressing well and raised expectations for its 2026 contribution. Khandelwal stated that Basler revenue contribution is now expected at $135 million to $140 million for 2026, with earnings contribution projected at $0.25 to $0.3.

The company reported an Industrial adjusted EBITDA margin of 22.6%, supported by volume leverage and favorable mix. Executives said the acquisition expands exposure to energy and industrial infrastructure opportunities.

Littelfuse Advances Portfolio StrategyLittelfuse continued its effort to optimize its power semiconductor portfolio, focusing resources on higher-value applications where management sees stronger competitive positioning. The company said power semiconductor demand improved during the quarter.

Khandelwal discussed the planned closure of the Allen, TX power semiconductor facility, describing it as part of a broader footprint optimization effort. The closure is expected to support profitability improvements in the Electronics segment beginning in 2027.

The Electronics segment posted 21% sales growth, including 20% organic growth, driven by passive products and semiconductor demand. Adjusted EBITDA margin expanded to 26.3% due to volume leverage, mix and operational execution.

LFUS Addresses Investor QuestionsA Baird analyst asked about the company’s ability to capitalize on improving demand and potential share gains. Henderson said Littelfuse was seeing broad momentum and remained focused on capturing growth through customer relationships and design wins.

A Needham analyst questioned record bookings and whether demand reflected replenishment or end consumption. Management said channel inventory remained healthy and characterized demand trends as largely driven by underlying customer demand.

Analysts also asked about margins and operational leverage. Khandelwal attributed improving profitability to volume leverage, operational execution and a favorable revenue mix.

Littelfuse Maintains Growth FocusLittelfuse guided third-quarter revenues of $780 million to $800 million, suggesting approximately 26% growth at the midpoint. The company expects adjusted EPS of $4.85 to $5.05, supported by continued demand and Basler contributions.

Management said third-quarter expectations include 21% organic growth, a 6% contribution from Basler and a 1% foreign exchange headwind. Executives also pointed to record bookings and a book-to-bill ratio well above 1.0 as indicators of continued customer momentum.

The company ended the quarter with $628 million of cash, a consolidated net leverage ratio of approximately 0.8 times and increased its quarterly dividend by 7% to $0.8 per share.

Zacks Rank and Style ScoresLFUS carries Zacks Rank #3 (Hold), indicating that earnings estimate revisions may not currently provide a strong directional signal. The Zacks Rank can change as analysts update earnings estimates following new company developments and quarterly results.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The stock has a Value Score of D, Growth Score of B, Momentum Score of A and VGM Score of B. Zacks Style Scores are designed to complement the Zacks Rank by evaluating characteristics such as value, growth and momentum, with higher grades representing stronger attributes within each category.

Key Takeaways HubSpot is expected to post higher Q2 2026 revenues, supported by AI adoption and platform expansion.HUBS may benefit from Breeze AI adoption, including Customer Agent, Prospecting Agent and Data Agent.HUBS may benefit from enterprise demand, multi-hub adoption and higher recurring revenue per customer. HubSpot, Inc. (HUBS - Free Report) is set to report second-quarter 2026 results on Aug. 5, after the closing bell. In the last reported quarter, the company delivered an earnings surprise of 10.12%. It pulled off a trailing four-quarter earnings surprise of 4.97%, on average, beating estimates on all previous occasions.

The company is expected to record year-over-year revenue growth, driven by continued execution of its long-term growth strategy and sustained momentum across its business. Ongoing innovation, expanding platform capabilities and disciplined execution are likely to have aided its overall quarterly results.

Factors at PlayGrowing adoption of HubSpot's Breeze artificial intelligence (AI) platform is expected to have lifted second-quarter 2026 performance. Increased usage of AI-powered capabilities, including Customer Agent, Prospecting Agent and Data Agent, is likely to have strengthened customer engagement and expanded adoption across its customer base.

During the to-be-reported quarter, higher adoption of Core Seats and AI credits is expected to create incremental monetization opportunities and support subscription revenue growth. Management also expects AI-driven seats and AI credit consumption to become additional long-term revenue drivers.

During the quarter under review, HubSpot is expected to have benefited from continued enterprise adoption of its unified customer platform. Increasing demand from businesses seeking to consolidate their marketing, sales and customer service operations is likely to have supported larger customer wins and greater multi-hub adoption. These trends are likely to have increased annual recurring revenue per customer, while expanding the company's recurring revenue base.

HubSpot is expected to have continued expanding its customer base during the June quarter, driven by the underpenetrated mid-market opportunity and pricing initiatives, including lower entry pricing, the removal of seat minimums, and the transition to the updated pricing model. These initiatives are likely to have generated healthy revenues during the quarter.

For the June quarter, the Zacks Consensus Estimate for total revenues is pegged at $897.8 million, indicating an increase from $761 million recorded a year ago. The consensus mark for earnings is pegged at $3.02 per share, implying growth from $2.19 reported in the prior-year quarter.

Earnings WhispersOur proven model does not predict an earnings beat for HubSpot for the second quarter. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here.

Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: HubSpot sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Stocks to ConsiderHere are some companies you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season:

Sandisk Corporation (SNDK - Free Report) has an Earnings ESP of +4.13% and sports a Zacks Rank #1 at present. It is set to release its fourth-quarter fiscal 2026 numbers on Aug. 5.

The Earnings ESP for Motorola Solutions, Inc. (MSI - Free Report) is +0.52%, and it carries a Zacks Rank of 2 at present. The company is scheduled to report second-quarter 2026 numbers on Aug. 5.

The Earnings ESP for Arista Networks Inc (ANET - Free Report) is +3.08%, and it carries a Zacks Rank of 2 at present. The company is scheduled to report second-quarter 2026 numbers on Aug. 4.

Live Coverage Updates appear automatically as they are published.

Live Updates 7 minutes ago

Live

Reddit (NYSE:RDDT | RDDT Price Prediction) reports at 4:05 PM ET, with Polymarket pricing a 91.5% chance of a beat.

Top 5 Analyst Questions Progress toward the 100 million US DAU goal from Q1’s ~50 million Sustainability of 74% ad revenue growth while lapping tough Q2 2025 comps AI licensing economics and the reported Google data-access dispute Reddit Max adoption beyond the initial thousands of advertisers Pace of the $1 billion buyback after only $5 million repurchased in Q1 Key Topics Management Must Address H2 revenue outlook and advertiser commitment cycles Gross margin trend after 91.5% in Q1 International monetization runway Buzzwords to Listen For “One-of-one,” “authentic human conversation,” “age of AI,” “flywheel” Red Flags Shorter advertiser planning cycles Guidance below the Street Any softening in US ARPU growth from 54% 9 minutes ago

Live

Bull Case Reddit (NYSE:RDDT) has beaten revenue estimates every quarter shown, with Q1 2026 EPS of $1.01 vs. $0.5639 and ad revenue up 74% YoY. Adjusted EBITDA margin hit 40.1%; FCF surged +145.79% YoY. Polymarket traders assign a 91.5% beat probability; analyst consensus target sits at $227.30. International DAU growth of +26% plus AI licensing renewals with Google and OpenAI expand the monetization runway. Bear Case Q4 2025 EPS missed by -14.48%, sending shares down roughly 9%. Shares are down 22.57% YTD, and options imply a 12% post-earnings move. CEO Steve Huffman sold shares as recently as July 15, 2026, dampening insider sentiment. International ARPU of $2.02 lags US ARPU of $9.63, exposing a wide monetization gap. 1 hour ago

Live

Reddit reports Q2 2026 earnings at 4:05 PM ET after today’s close, with management guiding for revenue between $715 and $725 million. Prediction-market traders currently assign a 91.5% probability that the company beats earnings expectations.

The bigger questions involve the breadth of Reddit’s advertising funnel, US daily active user growth, and momentum from AI data-licensing agreements. Reddit trades at about 24x forward earnings while generating roughly 95% of its revenue from advertising.

A strong report with raised guidance could reinforce the company’s AI-era community moat, but a softer advertising outlook could reopen the growth-deceleration debate that pressured shares earlier this year.

Reddit (NYSE:RDDT) reports Q2 2026 earnings results tonight at about 4:05 PM ET. Shares trade at around $178.34, down 22.57% year to date but up 20.89% from this time last year.

Momentum Meets a Higher Bar Reddit crushed Q1 2026 with EPS of $1.01 against a $0.5639 consensus, a 79.11% beat. Revenue reached $663.41 million, growing 69.08% year over year on $625 million in advertising (+74% YoY).

Daily active uniques hit 126.8 million, up 17%, while adjusted EBITDA margin expanded to 40.1%. Free cash flow of $311.16 million jumped 145.79%, underscoring the capital-light model.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Reddit didn't make the cut. Grab the names FREE today.

Consensus Estimates Metric Q2 2026 Estimate YoY Change FY 2026 Context Revenue (Company Guide) $715M to $725M ~+44% to +45% FY 2025 revenue: $2.20B EPS (Normalized) $0.99 n/a FY 2025 EPS: $2.62 Adj. EBITDA (Guide) $285M to $295M n/a Q1 26 margin: 40.1% The guidance implies a deceleration in revenue growth from Q1’s 69% pace, though EBITDA leverage continues to expand. With 21 buy ratings and a $227.30 consensus target, the bar sits above the reported number.

What I’ll Be Watching: Ad Funnel, DAU, and Data Licensing Tonight I’ll be watching whether Reddit’s ad revenue clears the top end of guidance, driven by strength across the top-15 verticals. Dynamic Product Ads posted a 91% ROAS lift in Q1, and Reddit Max campaigns delivered 17% lower CPA with 25%+ more conversions. Positive results here will validate the pricing story.

The US DAU trajectory will also be important to watch against the 100 million long-term target and international momentum, with machine translation in over 30 languages continuing to roll out across the UK and France.

Investors are eager to hear any updates on the Google data-access negotiations, which retail investors have flagged as a bullish catalyst. The company’s buyback pace matters too, as only $5 million of the $1 billion share repurchase authorization was deployed in Q1.

Earnings History Quarter EPS Surprise Day-Of Move 1-Week Move 30-Day Move Q1 2026 +79.11% +13.07% -6.42% +1.81% Q4 2025 -14.48% -7.43% -0.13% -1.94% Q3 2025 +53.79% +7.47% -6.88% +5.69% Q2 2025 +138.35% +17.47% +14.21% +18.29% On average, shares moved -0.79% one week after earnings over the past year.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Reddit didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

Space Exploration Technologies (SPCX -0.34%), better known as SpaceX, priced shares for $135 in its June 2026 initial public offering (IPO). The stock has since fallen nearly 16% to $113.5 as of July 27.

A $1,000 investment at the IPO price would have purchased about 7.41 shares and would now be worth roughly $841 as of this writing. However, that calculation assumes the investor received shares at the IPO price, which was not guaranteed for every retail investor. Strong investor demand and a limited supply of publicly traded shares helped drive SpaceX stock higher after its IPO. Investors reportedly submitted more than $250 billion in orders for the SpaceX IPO, while less than 5% of the company's shares were initially available for trading. The stock later lost much of its early gain as investors questioned its lofty valuation.

Image source: Getty Images

Against this backdrop, SpaceX's long-term share price trajectory depends heavily on whether the Starlink satellite internet business can continue to grow profitably and the next-generation Starship reusable rocket system can become a reliable commercial business.

Starlink remains the profit engine SpaceX's connectivity segment, powered mainly by Starlink, generated $3.26 billion in revenue and $1.19 billion in operating profit in the first quarter. However, the operating profit can be misleading because SpaceX does not expense the full cost of launching Starlink satellites immediately. Instead, it capitalizes those internal satellite and launch costs in the Connectivity segment and recognizes them gradually through depreciation. In the first quarter, depreciation from capitalized satellite and launch costs added $276 million to Connectivity's cost of revenue.

Today's Change

(

-0.34

%) $

-0.39

Current Price

$

112.17

Anthropic has also agreed to pay SpaceX $1.25 billion per month for computing capacity through May 2029, although fees are lower during the May and June 2026 ramp-up period.

While that contract could eventually make AI a larger source of revenue, the AI segment is still loss-making. SpaceX's AI segment posted a $2.47 billion operating loss in the first quarter, showing that rapidly rising compute revenue may not immediately translate into profits. Hence, for now, Connectivity segment remains the company's main source of operating profit.

SpaceX will report second-quarter results on Aug. 4. Around 911.5 million shares held by employees and early investors could become eligible for sale soon after this earnings report. While not all the eligible shareholders may sell the stock immediately, even a partial release could sharply increase the stock's available supply and add to near-term volatility.

SpaceX's planned $60 billion stock-funded Cursor acquisition would dilute existing shareholders if completed. Additionally, the $25 billion bond offering adds interest costs as the company continues investing heavily in artificial intelligence (AI), Starship, and other ambitious projects.

Starship is also expected to become a key growth catalyst. The rocket is designed to carry up to 60 higher-capacity Starlink V3 satellites per launch, potentially deploying 20 times more network capacity than the currently used Falcon 9 rocket. However, SpaceX must still prove that Starship can launch and be reused reliably enough to lower costs and improve Starlink's economics.

SpaceX is trading at roughly 38.5 times the analyst consensus 2026 revenue estimate of $39.3 billion. The premium valuation assumes major success across several businesses that are not yet profitable or fully commercial.

SpaceX could eventually justify a premium if Starlink maintains strong margins, Starship becomes dependable, and AI segment becomes profitable.

Meta Platforms Inc (NASDAQ:META, XETRA:FB2A, SIX:FB) shares fell as much as 10% on Thursday morning after the company's third-quarter results left investors unconvinced that its massive artificial intelligence spending is translating into tangible returns.

Earnings per share came in at $6.18, well below the $7.22 analysts had expected, even as revenue of $60.8 billion topped forecasts of $60.17 billion. Meta's guidance for the current quarter also fell short, with the company projecting sales of $62.5 billion versus estimates of $63.15 billion.

Total costs rose 55% year-over-year to $42.03 billion, with more than $1 billion of that tied to severance pay following a round of layoffs.

On the earnings call, Meta CEO Mark Zuckerberg declined to offer specific capex guidance for 2027, saying infrastructure planning "remains highly dynamic."

"We're gearing our current infrastructure plans toward maximizing capacity in 2026 and 2027, while giving us the flexibility to continue growing in 2028 and beyond," he said.

Reality Labs, the division behind Meta's virtual reality headsets and wearable AI devices, reported a $4.6 billion loss on sales of $431 million for the quarter.

Zuckerberg said demand for AI compute continues to outstrip supply. "There's just nowhere near enough compute for all the demand," he said. "We're getting a large number of offers for the compute that we have, but we also have a lot of internal uses that we think are going to be quite valuable."

On financing its infrastructure buildout, Meta said it has been shifting toward more debt. "We've been evolving our capital structure in recent years to include a greater mix of debt as we work to bring down our cost of capital," the company said, adding it has "generally found it prudent to continue adding cost-efficient, long-duration sources of capital."

The selloff extends a difficult stretch for Meta stock, which had already fallen for 10 consecutive trading sessions heading into the results, its longest losing streak on record.

Analysts at BofA said the after-hours pressure did not appear to reflect weakening fundamentals, pointing to a 10% rise in time spent on Instagram and a third-quarter revenue outlook implying accelerating two-year growth. Instead, they attributed the drop to investor concerns over Meta's spending direction, compounded by higher stock-based compensation.

XTB research director Kathleen Brooks said investors are still waiting for clearer signs that Meta's AI investments are paying off.

“It’s been a rough couple of weeks for Meta’s share price, which has traded lower for ten consecutive days, its longest losing streak in its history,” Brooks said.

“Although severance costs are only temporary and we could see profitability bounce back in Q3, we think that the sharp selloff in the Meta share price in the post-market is down to the astonishing burn rate of free cash flow.”

by Todd Bishop on Jul 30, 2026 at 10:14 amJuly 30, 2026 at 10:17 am

The first thing I do when Microsoft’s 10-K or 10-Q comes out is hit Ctrl-F and go waaaay down to the section called “Revenue, classified by significant product and service offerings.” It’s on Page 85 of the 10-K that came out Wednesday with its quarterly and annual results.

From my perspective, this gives the clearest view of what’s actually happening in Microsoft’s business. It groups things into categories and product names that match a real-world understanding of the company, as opposed to the mumbo jumbo you have to decode otherwise.

Microsoft reports its results in three broad segments: Productivity and Business Processes, Intelligent Cloud, More Personal Computing. Businesses like Azure, Xbox, Windows and LinkedIn all basically disappear inside them, until you dig into the filing.

The table, as it appears in Microsoft’s 10K for FY2026. Overall, for the fiscal year ended June 30, Microsoft’s revenue increased 18%, or $50.1 billion, to $331.8 billion. Here is what the 10-K table shows about the real drivers of the business.

Two business lines are driving nearly all of Microsoft’s growth.

Of the $50.1 billion in revenue that Microsoft added for the fiscal year, $31 billion came from Server products and cloud services, accounting for 62% of the company’s growth.

This category includes Azure, along with SQL Server, Windows Server, Visual Studio, GitHub and Nuance. Microsoft doesn’t detail Azure revenue in its financial statements, but CEO Satya Nadella said on the earnings call that Azure passed $100 billion in annual revenue for the first time this year.

At total revenue of $129.4 billion, this is by far Microsoft’s biggest business, accounting for nearly 40% of its annual revenue.

The second biggest growth came from Microsoft 365 Commercial, which added $14.2 billion in revenue, up 16% to $102 billion. Microsoft 365 Commercial covers the business subscriptions: Office, Teams, SharePoint, Exchange, security and compliance, and Microsoft 365 Copilot.

Taken together these two business lines produced 90% of Microsoft’s growth for the year.

They’re also where the company is monetizing AI most successfully: Azure, AI infrastructure and GitHub Copilot in server and cloud; and Microsoft 365 Copilot in Microsoft 365 Commercial.

Two of Microsoft’s longtime businesses got smaller.

Windows and Devices revenue fell $230 million, to $17.1 billion. Once the biggest growth engine for the company as a whole, the PC operating system business has been flat for the past four years, using the categories as Microsoft now defines them. Xbox revenue fell $1.7 billion, to $21.8 billion. That’s the first annual decline since Microsoft completed its $69 billion Activision Blizzard acquisition. It comes as Microsoft overhauls the business, cuts jobs and takes a write-down on unspecified Xbox assets. Other notes and observations from the table:

LinkedIn, at $19.8 billion, now generates more revenue than Windows and Devices. It passed Windows in fiscal 2025 and extended the lead this year, growing 11% while Windows declined. Microsoft 365 Consumer was the fastest-growing category after server products, up 24% to $9.2 billion. Search advertising grew 9% to $15.2 billion, and is closing in on Windows and Devices. Dynamics grew 15% to $9 billion. Enterprise and partner services, the consulting business, grew 6% to $8.3 billion. Thoughts? Let me know on LinkedIn. Here’s our coverage of the earnings.

The company never disclosed OpenAI‘s backlog outright. Instead, Hood told analysts that commercial RPO “increased 25% when excluding OpenAI.” Combined with Microsoft’s prior-year disclosures, that comment offers investors a way to estimate just how significant the ChatGPT maker has become to Microsoft’s future revenue pipeline.

If the estimate is directionally correct, it means roughly one out of every three dollars in Microsoft’s contracted commercial revenue pipeline is tied to a single customer. That’s an unusually high level of concentration for a company of Microsoft’s size, even as the company works to diversify its AI business.

The Math Behind Microsoft’s OpenAI ExposureMicrosoft reported commercial RPO of $368 billion at the end of fiscal 2025. If that backlog grew 25% excluding OpenAI, as Hood said, Microsoft’s commercial RPO without its AI partner would now stand at roughly $460 billion.

That leaves an implied $218 billion difference between Microsoft’s reported $678 billion backlog and the estimated $460 billion excluding OpenAI. In other words, OpenAI-related commitments could represent about 32% of Microsoft’s commercial backlog.

This assumes OpenAI was a negligible part of the backlog a year ago. If it wasn’t, the non-OpenAI base would be smaller—making OpenAI’s share bigger than 32%, not smaller. Either way, one-third is a floor.

Microsoft did not disclose OpenAI’s backlog or say one-third of its RPO belongs to the company. The figure is an estimate derived from Microsoft’s reported RPO and Hood’s disclosure about growth excluding OpenAI. Still, it highlights the extraordinary scale of Microsoft’s commercial relationship with its biggest AI partner.

Microsoft Is Diversifying Beyond OpenAIThe disclosure came as Microsoft spent much of the earnings call emphasizing that its AI strategy extends well beyond OpenAI.

CEO Satya Nadella said Azure now offers more than 11,000 AI models, including offerings from OpenAI, Anthropic, Mistral, xAI and Microsoft’s own MAI family. He also said the number of customers building applications with models from multiple providers has increased fivefold since the start of the year, underscoring Microsoft’s push toward a model-agnostic AI platform.

Even so, OpenAI remains a major growth engine. Hood also said commercial bookings increased 18% year over year excluding OpenAI, while commercial RPO grew 25% on the same basis, illustrating the outsized contribution the AI startup continues to make.

Why It Matters For InvestorsMicrosoft has increasingly positioned Azure as the infrastructure layer for the broader AI ecosystem rather than a platform tied to any single model provider. But the company’s latest disclosures suggest OpenAI remains one of the most strategically important customers in its history.

While the implied $218 billion figure is based on investor calculations rather than a company disclosure, it offers a fresh perspective on the scale of Microsoft’s AI partnership—and why investors continue to watch that relationship as closely as Azure’s headline growth.

Image via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

While Mastercard reported another quarter of double-digit revenue growth Thursday (July 30), executives devoted much of their second-quarter earnings discussion to explaining why agentic artificial intelligence could strengthen the economics of the card network.

AI may change where commerce begins, but Mastercard said it won’t change what makes payments work.

Mastercard CEO Michael Miebach said during the Thursday conference call that Mastercard views agentic commerce as “the next evolution in payments,” and within that evolution, the company expects its Agent Pay platform to extend existing network capabilities into AI-driven shopping.

Miebach drew a distinction between AI deciding what to buy and the infrastructure needed to complete the purchase. Merchants still need broad acceptance, predictable payment experiences and protections, while consumers need a way to challenge purchases made by autonomous software.

“We really believe that cards will prevail in that world,” Miebach said. “The card infrastructure, the card ecosystem, and the Mastercard proposition within that is unique.”

One reason is a capability Mastercard calls Verifiable Intent, developed with Google as part of Agent Pay, he said.

“Verifiable intent allows you to basically challenge a transaction and say, ‘I never wanted to buy this,’” Miebach said, adding that existing chargeback processes can then resolve disputes involving AI-assisted purchases.

AI could create entirely new payment categories, Miebach said. Consumer purchases can continue to flow over existing card infrastructure. Machine-to-machine transactions, however, could require different settlement mechanisms because AI systems may buy data, APIs and computing services at high speed and very low values.

“There could be an entirely new range of transactions,” he said, pointing to Mastercard’s Agent Pay for Machines initiative, which supports those interactions while allowing settlement over multiple types of rails.

Meanwhile, rather than presenting digital assets as a replacement for traditional payments, Miebach described stablecoins as another settlement option that still requires a trusted network.

“Stablecoins are not the answer to everything,” Miebach said.

Consumers and businesses still need acceptance, protections and interoperability across different coins and blockchains, which is why Mastercard continues investing in initiatives such as Open USD and its pending acquisition of BVNK.

The discussion came against a backdrop of healthy operating results.

Chief Financial Officer Sachin Mehra said currency-neutral net revenue increased 12% during the quarter, while adjusted net income rose 16%. Value-Added Services and Solutions revenue climbed 18%, worldwide gross dollar volume increased 8%, and cross-border volume grew 12%. Contactless represented 80% of in-person switched purchase transactions globally, while tokenized transactions exceeded 40% of all switched transactions.

Mehra also said underlying spending trends remained steady after the quarter ended.

Switch metrics were generally in line with Q1, and underlying spend remained stable, Mehra said, adding that the first four weeks of July remained “relatively stable and strong.” Excluding the Capital One debit portfolio migration, U.S. switch volume growth accelerated sequentially as fuel spending strengthened and both consumer and business spending continued to perform well. Cross-border growth also benefited from improving travel trends and increased card-not-present spending originating from Venezuela.

Asked whether U.S. spending strength was concentrated among affluent households, Mehra said it remained broad-based.

“We see it across credit and debit; we see it across consumer and commercial,” he said.

While affluent spending continues to grow somewhat faster, Mastercard continues to see healthy demand across both mass-market and affluent consumers, Mehra added.

Cybersecurity also was part of the larger discussion during the earnings call. Miebach said AI is increasing demand for fraud prevention, identity and cyber services, making security a larger part of Mastercard’s growth strategy alongside payments. The company said its Threat Intelligence platform has identified more than 7 million card-testing attacks across 192 countries, preventing an estimated $172 million in fraud, while acquisitions such as Recorded Future are expanding those capabilities beyond traditional card transactions.

Shares were up 2.4% early Thursday afternoon.

For all PYMNTS AI coverage, subscribe to the daily AI Newsletter.

By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Two of the new bubbly drinks from Starbucks. Starbucks Starbucks CEO Brian Niccol is ready for some fizz.

The company is testing a carbonated version of its Refreshers, which are iced juice and tea drinks often mixed with fruit pieces, that have become one of Starbucks' biggest beverage businesses since launching in 2012.

"I'm really excited that we're getting ready to go test sparkling. We're calling it Spritzers," he told investors on the company's third quarter earnings call Wednesday. The company delivered net sales of $9.3 billion for the period, with global comparable sales growth of 7.9%.

Of course, sparkling drinks have been a fast food chain staple since the beginning of the industry. After all, what's a Big Mac without a Coke?

But lest you think the Seattle coffee giant is apparently just now getting the memo on soda, Niccol says his baristas are taking a distinctive approach to bubbles.

"Our team does a great job on getting to the delicious flavors that are relevant for the customer. So it's been a really strong platform for us, and over the last quarter, really continued to perform," he said.

Starting this week, the company said it was testing out the spritz concept at about 100 stores in Austin, San Antonio, and St. Louis.

This is not a Coke. It's a Sparkling Cold Brew Sour Spritz  Starbucks The category expansion for Starbucks follows new Energy refreshers and Blended refreshers options rolled out earlier this summer. It also comes after nearly two years of a Niccol-led focus on fundamentals, like craft coffee and quicker, friendlier service.

One goal of the change is to increase business during the afternoon, once the morning coffee rush has subsided. The non-coffee flavors also help attract younger customers to the brand.

The sparkling flavor lineup includes a coffee and citrus combo, a peach and passion fruit tea, and a strawberry matcha mashup.

"It's been a platform, frankly, that we kind of got a little complacent on in the past, and now we are reinvigorating," Niccol said on the earnings call. "Whether it's fully decaffeinated or whether it's fully boosted, those are the different occasions that people want Refreshers, whether it's in the morning or the afternoon, and whether you're young or old, the platform is resonating."

Read next

Dominick Reuter You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Dominick Reuter is a senior retail reporter for Business Insider, primarily covering Walmart, Target, and Costco. His stories tend to focus on issues and trends that affect employees and customers.Prior to joining BI in 2019, Dominick worked for more than a decade as an independent photojournalist covering a wide range of stories for global wire services and newspapers, including Reuters, the Wall Street Journal, and Agence France-Presse.Dominick studied photojournalism at Boston University and later earned a Masters in business and economics journalism from Columbia University.If you're an employee or customer with a story to share, please contact me via email or text/call/Signal at 646-768-4750.

Fast Food Drinks Starbucks More

@Shopify has added $USDC payment support to its core payments stack, with @Arbitrum among the supported networks. The integration allows over 480 compatible digital wallets to execute retail transactions directly through Shopify Payments, positioning stablecoins as a practical alternative to traditional card networks for merchants worldwide.

How It Works at Checkout Shopify has wired USDC directly into its payments stack, allowing merchants to accept digital dollars at checkout without adding new providers or changing existing workflows. The feature sits inside Shopify Payments, meaning merchants can enable it alongside credit cards and other payment options.

Shopify Payments accepts $USDC on five networks: Base, Ethereum L1, Optimism, Polygon, and Arbitrum, with access through 480-plus supported crypto wallets and no gas fees charged to the buyer. Crucially, no foreign exchange fees apply either, removing two of the most common friction points for cross-border commerce.

Customers can pay with USDC on Ethereum, Base, or other chains, and funds bridge automatically, so the merchant does not need to think about which network the buyer used.

Settlement Options and Merchant Flexibility On the back end, merchants can choose whether to receive funds in traditional fiat payouts or settle in USDC on-chain. Shopify states that USDC payments convert to local currency by default, with no foreign exchange or multi-currency fees, and deposit to the connected bank account.

The integration is built in partnership with Stripe and Coinbase for wallet connectivity and transaction processing, with settlement occurring on Base and support for USDT planned.

The move reflects a broader shift in commerce infrastructure. Stablecoin payments reached $1.1 trillion in transaction volume in 2024, with Visa and Allium Labs confirming that stablecoins processed 2.5 times Visa's adjusted transfer volume that same year. For merchants processing high volumes of cross-border transactions, the economics are hard to ignore.

PYMNTS: Shopify Signals Stablecoin Preferences With USDC Integration
Digital Applied: Shopify Spring 2026 Checkout and Payments Updates
Shopifreaks: Shopify Adds USDC Stablecoin to Its Core Payments Stack

Blockchain

30 July 2026 | 20:11 Open USD will launch on Ethereum from its first day of operation as part of a broader multichain rollout that also includes Solana, Base, Stellar and Polygon.

The July 30 announcement from Ethereum Institutional confirms the network’s inclusion and highlights its role in the stablecoin’s business-focused settlement infrastructure.

As we previously reported, more than 140 companies have joined Open Standard, including Visa, Mastercard, Stripe, BlackRock and BNY. Under the proposed model, most reserve income would be shared with businesses that distribute and use the stablecoin instead of remaining entirely with a single issuer.

Why Ethereum Matters to Open USD Ethereum offers payment companies a shared settlement network without placing the underlying ledger under the control of any one participant.

That matters when companies such as Visa, Mastercard and Stripe are expected to use the same infrastructure. Each can verify the asset and its settlement rules without relying on a private system operated by a direct competitor.

Ethereum also brings established liquidity, mature infrastructure and familiarity among institutional market participants. Other supported networks can then handle transfers where lower fees or faster execution matter more.

Breaking: Open USD will launch on @ethereum on day one.

Over 140 businesses, including Visa, Mastercard, Stripe, BlackRock and BNY. All reserve earnings flow to the partners that grow it.

A shared asset needs neutral ground.

We’re excited to be working with @openstandard on… pic.twitter.com/WF3ure6Dhb

— Ethereum Institutional (@ethereuminsti) July 30, 2026

Open USD Is Being Built for Business Use Open USD is being positioned mainly for corporate settlement, cross-border treasury activity, payment processors and institutional liquidity rather than retail trading.

Consumers may therefore use it without interacting with the stablecoin directly. A merchant, payroll platform or remittance service could settle through Open USD behind the scenes while customers continue paying and receiving funds in local currency.

Its business model is also different from those of USDT and USDC. Participating companies that help distribute Open USD are expected to receive a share of the reserve earnings. That could give exchanges, payment firms and fintech platforms a financial reason to integrate it, although ordinary token holders are not automatically entitled to yield.

Ethereum Fees Will Matter Most to Businesses Ethereum transaction costs remain a practical consideration, especially for treasury desks, payment processors and other companies handling large volumes.

These firms can reduce costs by batching transfers, settling larger amounts less frequently or routing smaller transactions through cheaper supported networks. Ethereum is more likely to serve high-value settlement and liquidity needs than individual purchases at checkout.

Its inclusion from day one gives Open USD access to a major institutional market. Support for several networks broadens the stablecoin’s potential use across payments, trading and treasury operations without requiring all activity to pass through Ethereum mainnet.

Author

Alex is Editor-in-Chief of Coindoo and co-founder of Millennial Media Group, with nearly a decade of experience covering financial markets - crypto first, then everything else. It started in 2016 with Bitcoin. Like most people at the time, he didn't fully understand it - so he kept digging. Blockchain, tokenomics, the projects, the cycles. That curiosity never stopped, and eventually pulled him into traditional markets too: equities, commodities, macro. Not because he left crypto behind, but because you can't properly understand one without the other. What drives him is straightforward: he wants to know why something is happening, not just that it's happening. Most market coverage stops at the headline - price up, price down, here's a chart. Alex finds that kind of reporting actively unhelpful. If you walk away from an article without understanding the mechanism behind the move, what did you actually learn? He holds a degree in Tourism from New Bulgarian University - not the most obvious path into financial markets, but markets have a way of pulling in people who are simply too curious to stay out. He has authored over 200 in-depth analyses and more than 10,000 articles across crypto and traditional finance. He still thinks every day in markets teaches him something new. That's probably why he hasn't stopped.

Key Takeaways Palantir will report Q2 earnings on Aug. 3, with earnings seen rising 118.8% and revenues climbing 80%.Government revenues are projected to rise 65.7%, while Commercial revenues are expected to jump 98%.PLTR trades far above industry valuation multiples despite a 22% share-price decline over the past year. Palantir Technologies Inc. (PLTR - Free Report) will report its second-quarter 2026 results on Aug. 3, after the bell.

The Zacks Consensus Estimate for earnings in the to-be-reported quarter stands at 35 cents, indicating 118.8% growth from the year-ago reported quarter. The consensus estimate for total revenues stands at $1.81 billion, indicating 80% year-over-year growth. There have been no changes or revisions to analyst estimates lately.

                                                                Image Source: Zacks Investment Research

The company has a strong history of earnings surprises. Earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and matched it once, with an average earnings surprise of 11.6%.

PLTR’s Lesser Chance of Q2 Earnings BeatOur proven model doesn’t conclusively predict an earnings beat for PLTR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

PLTR has an Earnings ESP of 0.00% and a Zacks Rank #2.

You can see the complete list of today’s Zacks #1 Rank stocks here.

PLTR’s All-Round Healthy Business Should be the Driver in Q2We expect a significant year-over-year improvement in the company’s top line in the to-be-reported quarter, driven by healthy business from existing and new customers, strengthening both the Government and Commercial segments.

The consensus estimate for Government revenues is pegged at $916.2 million, indicating 65.7% year-over-year growth. The consensus mark for Commercial revenues is pegged at $892.1 million, suggesting 98% year-over-year growth.

PLTR Stock Experiencing PullbackPalantir shares have declined 22% over the past year and 15% over the past three months. This performance clearly indicates a pullback in the stock.

                                                              Image Source: Zacks Investment Research

Based on trailing 12-month EV-to-EBITDA, PLTR is currently trading at 162.72X, way above the industry’s 10.66X. If we look at the forward 12-month Price/Earnings ratio, the company’s shares are currently trading at 67.27X forward earnings, well above the industry’s 26.51X.

Investment ConsiderationsPalantir continues to distinguish itself through rapid commercial adoption, expanding customer relationships, improving profitability, and disciplined execution. The company's Artificial Intelligence Platform is gaining traction across enterprises, while larger contracts and a growing customer base provide visibility into sustained long-term growth. At the same time, exceptional operating efficiency demonstrates that Palantir is scaling its business without compromising profitability. So, the recent share-price weakness appears to present a compelling opportunity for long-term investors. Despite near-term valuation concerns, Palantir's strengthening fundamentals support a Buy recommendation for investors seeking exposure to one of the software industry's leading AI growth stories.

Peer ViewPLTR’s competitive strengths are reflected in its financial performance. The company delivered 85% revenue growth in the first quarter of 2026, including an exceptional 133% increase in U.S. commercial revenues, while generating a 60% adjusted operating margin and a 53% GAAP net margin. Even leading AI software companies like Datadog (DDOG - Free Report) and Snowflake (SNOW - Free Report) struggle to match this combination of rapid expansion and profitability.

While DDOG and SNOW continue to benefit from AI demand, their growth rates remain significantly lower. By combining a durable software foundation with industry-specific expertise and superior execution, Palantir continues to separate itself from DDOG, SNOW and traditional enterprise software competitors.

Repatha ist der einzige PCSK9-Hemmer, der in einer klinischen Phase-3-Studie nachweislich das Risiko eines ersten Herzinfarkts und Schlaganfalls signifikant senkt und damit neue Maßstäbe bei der Senkung kardiovaskulärer Risiken setzt.

Die Empfehlung stützt sich auf die bahnbrechende globale Phase-3-Studie „VESALIUS-Cardiovascular" mit mehr als 12.000 Patientinnen und Patienten.

, /PRNewswire/ -- Amgen (NASDAQ: AMGN) gab heute bekannt, dass der Ausschuss für Humanarzneimittel (Committee for Medicinal Products for Human Use, CHMP) der Europäischen Arzneimittelagentur (EMA) eine positive Stellungnahme zu Repatha® (Evolocumab) für Erwachsene mit nachgewiesener oder hohem Risiko einer atherosklerotischen Herz-Kreislauf-Erkrankung zur Senkung des kardiovaskulären Risikos durch Senkung des LDL-C-Spiegels als Ergänzung zur Korrektur anderer Risikofaktoren abgegeben hat. Die Empfehlung stützt sich auf die Ergebnisse der Phase-3-Studie VESALIUS-CV, die gezeigt hat, dass Repatha das Risiko für schwerwiegende unerwünschte kardiovaskuläre Ereignisse (Major Adverse Cardiovascular Events, MACE) bei Erwachsenen mit hohem Risiko, die zuvor weder einen Herzinfarkt noch einen Schlaganfall erlitten hatten, signifikant senkte, wenn es zusätzlich zu Statinen oder anderen LDL-C-senkenden Therapien verabreicht wurde.

„In Europa besteht nach wie vor ein erheblicher ungedeckter Bedarf, da viele Patientinnen und Patienten mit hohem kardiovaskulärem Risiko trotz der verfügbaren lipidsenkenden Therapien nicht in der Lage sind, die empfohlenen LDL-C-Werte zu erreichen", sagte Dr. med. Paul Burton, Ph.D., Chief Medical Officer bei Amgen. „Die positive Stellungnahme des CHMP spiegelt die Aussagekraft der klinischen Daten zu Repatha wider und bringt uns einen Schritt näher, wenn es darum geht, Repatha für mehr Patientinnen und Patienten verfügbar zu machen, die davon profitieren könnten." Repatha ist der einzige PCSK9-Hemmer, der in einer klinischen Phase-3-Studie nachweislich das Risiko eines ersten schwerwiegenden unerwünschten kardiovaskulären Ereignisses senkt. Sollte die Europäische Kommission dieser erweiterten Indikation zustimmen, könnte dies die kardiovaskuläre Versorgung geeigneter Patientinnen und Patienten in Europa grundlegend verändern."

Herz-Kreislauf-Erkrankungen sind weltweit die häufigste Todesursache.1 Aktuelle Forschungsergebnisse zeigen, dass mehr als 99 % der Menschen, bei denen erstmals ein kardiovaskuläres Ereignis auftritt, mindestens einen traditionellen Risikofaktor aufweisen, darunter einen hohen LDL-C-Spiegel, der zu den am besten beeinflussbaren Risikofaktoren für einen Herzinfarkt oder Schlaganfall zählt.2 Während die Leitlinien der Europäischen Gesellschaft für Kardiologie (European Society of Cardiology, ESC) und der Europäischen Gesellschaft für Atherosklerose (European Atherosclerosis Society, EAS) eine intensive Senkung des LDL-Cholesterinspiegels in Abhängigkeit vom kardiovaskulären Risiko empfehlen, liegen viele Hochrisikopatientinnen und -patienten trotz verfügbarer lipidsenkender Therapien weiterhin über den empfohlenen LDL-Cholesterin-Zielwerten.3

Repatha wurde in der Europäischen Union ursprünglich 2015 für die Behandlung von Erwachsenen und Kindern mit primärer Hypercholesterinämie oder gemischter Dyslipidämie sowie zur Senkung des kardiovaskulären Risikos bei Erwachsenen mit nachgewiesener atherosklerotischer kardiovaskulärer Erkrankung (Atherosclerotic Cardiovascular Disease, ASCVD) zugelassen. Es wird erwartet, dass die Europäische Kommission in den kommenden Monaten eine endgültige Entscheidung über den Antrag trifft.

Informationen zur VESALIUS-CV-Studie
VESALIUS-CV ist eine globale klinische Phase-3-Studie, die doppelblind, randomisiert und placebokontrolliert durchgeführt wird und darauf abzielt, den Einfluss einer Senkung des LDL-C-Spiegels durch Evolocumab auf MACE bei Erwachsenen mit hohem kardiovaskulärem Risiko ohne vorangegangenen Herzinfarkt oder Schlaganfall zu untersuchen. Die Ergebnisse wurden im November 2025 im New England Journal of Medicine veröffentlicht. Repatha führte zu einer relativen Risikoreduktion um 25 % für den kombinierten Endpunkt aus Tod durch koronare Herzkrankheit (KHK), Herzinfarkt oder ischämischem Schlaganfall (3-P-MACE) sowie um 19 % für einen erweiterten kombinierten Endpunkt, der zusätzlich jegliche ischämiebedingte arterielle Revaskularisation umfasste (4-P-MACE). Evolocumab senkte zudem das Risiko eines Herzinfarkts um 36 %. Bei allen drei Endpunkten zeigte sich ein konsistenter Vorteil von Evolocumab gegenüber Placebo, einschließlich eines um 36 % verringerten Risikos für einen Herzinfarkt. In einer Lipid-Teilstudie führte die Zugabe von Evolocumab zu einer maximal verträglichen Dosis eines Statins und/oder Ezetimib bei den beobachteten Partientinnen und Patienten zu einer deutlichen Senkung der LDL-C-Werte, wobei der Medianwert bei 45 mg/dl lag, verglichen mit 109 mg/dl in der Placebo-Gruppe.

In die VESALIUS-CV-Studie wurden mehr als 12.000 Patientinnen und Patienten mit bekannter ASCVD oder Hochrisikodiabetes aufgenommen, die keine Herzinfarkte oder Schlaganfälle in der Anamnese aufwiesen, einen LDL-C-Wert von ≥ 90 mg/dl, oder ein Nicht-HDL-Cholesterin (Non-HDL-C) von ≥ 120 mg/dL oder ein Apolipoprotein B von ≥ 80 mg/dL aufwiesen und mit der höchstverträglichen Dosis eines Statins und/oder Ezetimib behandelt wurden. Der Medianwert des LDL-C-Ausgangswerts lag bei lokalen Laboruntersuchungen bei 122 mg/dl (IQR: 104–149 mg/dl). Die Teilnehmenden wurden randomisiert und erhielten zusätzlich zu einer optimierten lipidsenkenden Therapie entweder Evolocumab oder ein Placebo; sie wurden über einen Median von etwa 4,6 Jahren nachbeobachtet.

Amgens Engagement für Innovationen im Bereich Herz-Kreislauf-Erkrankungen
Amgen definiert die kardiometabolische Versorgung neu – mit modernster, auf der Humanbiologie basierender Forschung, die sich mit eng miteinander verbundenen Herz-Kreislauf- und Stoffwechselerkrankungen befasst, die zu schwerwiegenden Folgen oder zum Tod führen können.

Kardiometabolische Erkrankungen treten häufig gemeinsam auf und können zu schwerwiegenden Folgen oder zum Tod führen, obwohl sie behandelbar sind.4 Trotz Fortschritten bei lipidsenkenden und metabolischen Therapien bleibt ein erhebliches kardiovaskuläres Restrisiko bestehen, das durch einen anhaltend erhöhten LDL-C-Spiegel, genetisch bedingtes Lp(a) und eine durch Adipositas bedingte kardiometabolische Dysfunktion verursacht wird.5

Auf der Grundlage von mehr als 40 Jahren Spitzenforschung und Humangenetik definiert Amgen die kardiometabolische Versorgung und das Risikomanagement neu. Nach jahrelangen Erfolgen bei Herz-Kreislauf-Erkrankungen mit Repatha ist Amgen gut aufgestellt, um potenziell bahnbrechende Medikamente wie MariTide und Olpasiran auf den Markt zu bringen, die dazu beitragen, die Bedürfnisse der Patientinnen und Patienten in der kardiometabolischen Versorgung zu erfüllen und die vielfältigen, miteinander verknüpften Ursachen von Herz-Kreislauf- und Stoffwechselerkrankungen anzugehen.

Informationen zu Repatha
Repatha ist ein humaner monoklonaler Antikörper, der die Proprotein-Convertase Subtilisin/Kexin Typ 9 (PCSK9) hemmt. Repatha bindet an PCSK9 und verhindert, dass zirkulierendes PCSK9 an den Low-Density-Lipoprotein (LDL)-Rezeptor (LDLR) bindet. Dadurch wird der durch PCSK9 vermittelte Abbau des LDLR verhindert und ermöglicht, dass der LDLR wieder an die Oberfläche der Leberzellen zurückgeführt wird. Durch die Hemmung der Bindung von PCSK9 an den LDLR erhöht Repatha die Anzahl der verfügbaren LDLR, die LDL aus dem Blut entfernen können, und senkt dadurch den LDL-C-Spiegel.

Repatha ist einer der am umfassendsten untersuchten PCSK9-Hemmer, für den klinische und praxisbezogene Erkenntnisse aus verschiedenen Patientengruppen und mit unterschiedlichen kardiovaskulären Risikoprofilen vorliegen.6 Der klinische Nutzen und die Sicherheit von Repatha wurden über einen Zeitraum von 15 Jahren in 51 klinischen Studien mit über 57.000 Patientinnen und Patienten untersucht.7 Repatha ist der einzige PCSK9-Hemmer, der sowohl in der Hochrisiko-Primär- als auch in der Sekundärprävention eine signifikante Reduktion kardiovaskulärer Ereignisse nachweisen konnte, wobei die Patientinnen und Patienten mit nur einmal alle zwei Wochen verabreichtem Repatha eine drastische Senkung des LDL-C-Spiegels erreichten und aufrechterhalten konnten.8,9

Repatha wurde erstmals 2015 zugelassen und wurde seitdem weltweit bei mehr als 10 Millionen Patientinnen und Patienten angewendet.10  Im August 2025 erweiterte die US-amerikanische Arzneimittelbehörde (U.S. Food and Drug Administration, FDA) den zugelassenen Anwendungsbereich von Repatha auf Erwachsene mit erhöhtem Risiko für schwerwiegende unerwünschte kardiovaskuläre Ereignisse aufgrund eines unkontrollierten LDL-C-Spiegels. Repatha ist in 74 Ländern zugelassen, darunter in den USA, in Japan, in Kanada, in Australien sowie in allen 28 Mitgliedstaaten der Europäischen Union.11 In weiteren Ländern sind Zulassungsanträge anhängig.

Wichtige Produktinformationen für die EU

In Europa ist Repatha für folgende Anwendungsgebiete zugelassen:

Hypercholesterinämie und gemischte Dyslipidämie
Repatha ist bei Erwachsenen mit primärer Hypercholesterinämie (heterozygot, familiär und nicht familiär) oder gemischter Dyslipidämie als Ergänzung zu einer Diät indiziert:

in Kombination mit einem Statin oder einem Statin und anderen lipidsenkenden Therapien bei Patientinneb und Patienten, welche die LDL-C-Zielwerte mit der maximal verträglichen Dosis eines Statins nicht erreichen können, oder allein oder in Kombination mit anderen lipidsenkenden Therapien bei Patientinnen und Patienten, die Statine nicht vertragen oder bei denen die Einnahme eines Statins kontraindiziert ist. Homozygote familiäre Hypercholesterinämie
Repatha ist bei Erwachsenen und Jugendlichen ab zwölf Jahren mit homozygoter familiärer Hypercholesterinämie in Kombination mit anderen lipidsenkenden Therapien indiziert.

Atherosklerotische Herz-Kreislauf-ErkrankungenRepatha ist bei Erwachsenen mit nachgewiesener atherosklerotischer Herz-Kreislauf-Erkrankung oder mit hohem Risiko dafür indiziert, um das kardiovaskuläre Risiko durch Senkung der LDL-C-Werte zu verringern, und zwar als Ergänzung zur Korrektur anderer Risikofaktoren:

in Kombination mit der maximal verträglichen Dosis eines Statins, mit oder ohne weitere lipidsenkende Therapien, oder allein oder in Kombination mit anderen lipidsenkenden Therapien bei Patientinnen und Patienten, die Statine nicht vertragen oder bei denen die Einnahme eines Statins kontraindiziert ist. Dosierung
Primäre Hypercholesterinämie und gemischte Dyslipidämie bei Erwachsenen

Die empfohlene Dosis von Repatha beträgt entweder 140 mg alle zwei Wochen oder 420 mg einmal monatlich; beide Dosierungen sind klinisch gleichwertig.

Homozygote familiäre Hypercholesterinämie bei Erwachsenen und Jugendlichen ab zwölf Jahren

Die empfohlene Anfangsdosis beträgt 420 mg einmal monatlich. Nach zwölf Wochen Behandlung kann die Dosierungshäufigkeit auf 420 mg einmal alle zwei Wochen erhöht werden, falls kein klinisch relevantes Ansprechen erzielt wird. Patientinnen und Patienten, die sich einer Apherese unterziehen, können die Behandlung mit 420 mg alle zwei Wochen beginnen, um sie an ihren Apherese-Zeitplan anzupassen.

Wichtige Sicherheitshinweise
Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Auf diese Weise lassen sich schnell neue Sicherheitsinformationen ermitteln. Medizinisches Fachpersonal wird gebeten, alle vermuteten Nebenwirkungen zu melden.

Kontraindikationen: Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile.

Besondere Warnhinweise und Vorsichtsmaßnahmen: Nierenfunktionsstörung: Patientinnen und Patienten mit schwerer Nierenfunktionsstörung (definiert als eGFR < 30 ml/min/1,73 m2) wurden nicht untersucht. Repatha sollte bei Patientinnen und Patienten mit schwerer Nierenfunktionsstörung mit Vorsicht angewendet werden. Leberfunktionsstörung: Bei Patientinnen und Patienten mit mäßiger Leberfunktionsstörung wurde eine Verringerung der Gesamtexposition gegenüber Evolocumab beobachtet, was zu einer geringeren Wirkung im Hinblick auf die Senkung des LDL-C führen kann. Daher kann bei diesen Patientinnen und Patienten eine engmaschige Überwachung erforderlich sein. Patientinnen und Patienten mit schwerer Leberfunktionsstörung (Child-Pugh-Klasse C) wurden nicht untersucht. Repatha sollte bei Patientinnen und Patienten mit schwerer Leberfunktionsstörung mit Vorsicht angewendet werden. Trockener Naturkautschuk: Die Nadelabdeckung der vorgefüllten Glasspritze und des vorgefüllten Pens besteht aus trockenem Naturkautschuk (einem Latexderivat), der allergische Reaktionen hervorrufen kann. Natriumgehalt: Repatha enthält weniger als 1 mmol Natrium (23 mg) pro Dosis, d. h., es ist im Wesentlichen „natriumfrei".

Wechselwirkungen: Für Repatha wurden keine formellen Studien zu Wechselwirkungen mit anderen Arzneimitteln durchgeführt. Es wurden keine Studien zu pharmakokinetischen und pharmakodynamischen Wechselwirkungen zwischen Repatha und anderen lipidsenkenden Arzneimitteln als Statinen und Ezetimib durchgeführt.

Fruchtbarkeit, Schwangerschaft und Stillzeit: Es liegen keine oder nur begrenzte Daten zur Anwendung von Repatha bei Schwangeren vor. Repatha sollte während der Schwangerschaft nicht angewendet werden, es sei denn, der klinische Zustand der Frau erfordert eine Behandlung mit Evolocumab. Es ist nicht bekannt, ob Evolocumab in die Muttermilch übergeht. Ein Risiko für gestillte Neugeborene/Säuglinge kann nicht ausgeschlossen werden. Es liegen keine Daten zu den Auswirkungen von Evolocumab auf die Fruchtbarkeit beim Menschen vor.  

Nebenwirkungen: In zulassungsrelevanten, kontrollierten klinischen Studien wurden die folgenden häufigen (> 1/100 bis < 1/10) Nebenwirkungen berichtet: Grippe, Nasopharyngitis, Infektion der oberen Atemwege, Hautausschlag, Übelkeit, Rückenschmerzen, Gelenkschmerzen, Reaktionen an der Injektionsstelle. Eine vollständige Beschreibung der Nebenwirkungen finden Sie in der  Fachinformation .

Vorsichtsmaßnahmen bei der Einnahme von Arzneimitteln: Im Kühlschrank lagern (2 °C – 8 °C). Nicht einfrieren. Bewahren Sie die Fertigspritze oder den Fertigpen in der Originalverpackung auf, um sie vor Lichteinwirkung zu schützen. Nach Entnahme aus dem Kühlschrank kann Repatha bei Raumtemperatur (bis zu 25 °C) in der Originalverpackung aufbewahrt werden und muss innerhalb eines Monats aufgebraucht werden.

INDIKATIONEN IN DEN USA
Repatha® ist ein PCSK9-Hemmer (Proprotein-Convertase-Subtilisin/Kexin Typ 9), der für folgende Indikationen zugelassen ist:

Zur Senkung des Risikos schwerwiegender unerwünschter kardiovaskulärer Ereignisse (kardiovaskulärer Tod, Myokardinfarkt, Schlaganfall, instabile Angina pectoris, die einen Krankenhausaufenthalt erfordert, oder koronare Revaskularisation) bei Erwachsenen mit erhöhtem Risiko für diese Ereignisse. Als Ergänzung zu einer Diät und körperlicher Bewegung zur Senkung des LDL-Cholesterins (LDL-C) bei: Erwachsenen mit Hypercholesterinämie. Erwachsenen und pädiatrischen Patientinnen und Patienten ab zehn Jahren mit heterozygoter familiärer Hypercholesterinämie (HeFH). Erwachsenen und pädiatrischen Patientinnen und Patienten ab zehn Jahren mit homozygoter familiärer Hypercholesterinämie (HoFH). Die Sicherheit und Wirksamkeit von Repatha® bei Kindern mit HeFH oder HoFH unter zehn Jahren sowie bei Kindern mit anderen Formen der Hypercholesterinämie wurden nicht nachgewiesen. Die vollständigen Verschreibungsinformationen finden Sie auf www.Repatha.com.

 WICHTIGE SICHERHEITSINFORMATIONEN

Kontraindikation: Repatha® ist bei Patientinnen und Patienten kontraindiziert, bei denen in der Vergangenheit eine schwere Überempfindlichkeitsreaktion auf Evolocumab oder einen der Hilfsstoffe in Repatha® aufgetreten ist. Bei Patientinnen und Patienten, die mit Repatha® behandelt wurden, sind schwere Überempfindlichkeitsreaktionen einschließlich Angioödemen aufgetreten. Überempfindlichkeitsreaktionen: Bei Patientinnen und Patienten, die mit Repatha® behandelt wurden, wurden Überempfindlichkeitsreaktionen, einschließlich Angioödemen, berichtet. Sollten Anzeichen oder Symptome schwerwiegender Überempfindlichkeitsreaktionen auftreten, ist die Behandlung mit Repatha® abzubrechen, die Patientinnen und Patienten gemäß den geltenden Behandlungsstandards zu behandeln und sie so lange zu überwachen, bis die Anzeichen und Symptome abgeklungen sind. Nebenwirkungen bei Erwachsenen mit primärer Hypercholesterinämie: Die häufigsten Nebenwirkungen (> 5 % der mit Repatha® behandelten Patientinnen und Patienten und häufiger als unter Placebo) waren: Nasopharyngitis, Infektion der oberen Atemwege, Grippe, Rückenschmerzen und Reaktionen an der Injektionsstelle.Aus einer Zusammenfassung der 52-wöchigen Studie und sieben 12-wöchigen Studien: Lokale Reaktionen an der Injektionsstelle traten bei 3,2 % der mit Repatha® behandelten Patientinnen und Patienten und bei 3,0 % der mit Placebo behandelten Patientinnen und Patienten auf. Die häufigsten Reaktionen an der Injektionsstelle waren Hautrötungen, Schmerzen und Blutergüsse. Überempfindlichkeitsreaktionen traten bei 5,1 % der mit Repatha®behandelten Patientinnen und Patienten und bei 4,7 % der mit Placebo behandelten Patientinnen und Patienten auf. Die häufigsten Überempfindlichkeitsreaktionen waren Hautausschlag (1,0 % gegenüber 0,5 % bei Repatha® bzw. Placebo), Ekzem (0,4 % gegenüber 0,2 %), Erytheme (0,4 % gegenüber 0,2 %) sowie Urtikaria (0,4 % gegenüber 0,1 %).

Unerwünschte Wirkungen in der FOURIER-Studie zu kardiovaskulären Endpunkten: Die häufigsten Nebenwirkungen (> 5 % der mit Repatha® behandelten Patientinnen und Patienten und häufiger als unter Placebo) waren: Diabetes mellitus (8,8 % Repatha®, 8,2 % Placebo), Nasopharyngitis (7,8 % Repatha®, 7,4 % Placebo) sowie Infektionen der oberen Atemwege (5,1 % Repatha®, 4,8 % Placebo).Unter den 16.676 Patientinnen und Patienten, die zu Studienbeginn keinen Diabetes mellitus hatten, betrug die Inzidenz eines neu auftretenden Diabetes mellitus während der Studie bei den mit Repatha® behandelten Patientinnen und Patienten 8,1 %, verglichen mit 7,7 % bei den Patientinnen und Patienten, die ein Placebo erhielten.

Nebenwirkungen bei pädiatrischen Patientinnen und Patienten mit HeFH: Die häufigsten Nebenwirkungen (> 5 % der mit Repatha® behandelten Patientinnen und Patienten und häufiger als unter Placebo) waren: Nasopharyngitis, Kopfschmerzen, Schmerzen im Mund- und Rachenraum, Grippe und Infektion der oberen Atemwege. Nebenwirkungen bei Erwachsenen und Kindern mit HoFH: In einer 12-wöchigen Studie mit 49 Patientinnen und Patienten traten bei mindestens zwei mit Repatha® behandelten Patientinnen und Patienten folgende Nebenwirkungen auf, die häufiger auftraten als unter Placebo: Infektionen der oberen Atemwege, Grippe, Gastroenteritis und Nasopharyngitis. In einer offenen Verlängerungsstudie mit 106 Patientinnen und Patienten, darunter 14 Kinder, wurden keine neuen Nebenwirkungen beobachtet. Immunogenität: Repatha® ist ein humaner monoklonaler Antikörper. Wie bei allen therapeutischen Proteinen besteht auch bei Repatha® das Potenzial für Immunogenität. Die vollständigen Verschreibungsinformationen finden Sie hier.

Informationen zu Amgen
Amgen erforscht, entwickelt, produziert und liefert innovative Medikamente zur Bekämpfung einiger der schwersten Krankheiten der Welt. Amgen nutzt das Beste aus Biologie und Technologie und erreicht mit seinen Medikamenten Millionen von Patienten.

Vor mehr als 45 Jahren trug Amgen an seinem US-Hauptsitz in Thousand Oaks, Kalifornien, zur Gründung der Biotechnologiebranche bei und ist nach wie vor führend in der Innovation, indem es Technologien sowie humangenetische Daten nutzt, um über das heute Bekannte hinauszugehen. Amgen entwickelt eine breite und tiefe Pipeline und ein Portfolio von Medikamenten zur Behandlung von Krebs, Herzkrankheiten, Entzündungen, seltenen Krankheiten sowie Fettleibigkeit und mit Fettleibigkeit verbundenen Krankheiten.

Amgen wurde  wiederholt  für seine Innovationskraft und seine Unternehmenskultur ausgezeichnet, unter anderem von Fast Company und Forbes. Amgen gehört zu den 30 Unternehmen, die den Dow Jones Industrial Average® bilden, und ist auch Teil des Nasdaq-100-Index®, der die größten und innovativsten nicht-finanziellen Unternehmen umfasst, die an der Nasdaq-Börse nach Marktkapitalisierung notiert sind.

Für weitere Informationen besuchen Sie Amgen.com und folgen Sie Amgen auf X, LinkedIn, Instagram, YouTube, Facebook, TikTok und Threads.

Zukunftsgerichtete Aussagen
Diese Pressemitteilung enthält zukunftsgerichtete Aussagen, die auf den aktuellen Erwartungen und Einschätzungen von Amgen beruhen. Alle Aussagen, mit Ausnahme von Aussagen über historische Tatsachen, sind Aussagen, die als zukunftsgerichtete Aussagen angesehen werden könnten, einschließlich jeglicher Aussagen zu den Ergebnissen, Vorteilen und Synergien von Kooperationen oder potenziellen Kooperationen mit anderen Unternehmen (einschließlich BeOne Medicines Ltd. oder Kyowa Kirin Co., Ltd.), die Geschäftsentwicklung von Otezla® (Apremilast), unsere Übernahmen von ChemoCentryx, Inc., Dark Blue Therapeutics, Ltd. oder Horizon Therapeutics plc (einschließlich der voraussichtlichen Geschäftsentwicklung und des Ausblicks für das Geschäft von Horizon, der Geschäftsentwicklung und der Chancen sowie etwaiger potenzieller strategischer Vorteile, Synergien oder Chancen, die infolge einer solchen Übernahme erwartet werden) sowie Schätzungen zu Umsätzen, operativen Margen, Investitionsausgaben, Liquidität, anderer Finanzkennzahlen, erwarteter rechtlicher, schiedsgerichtlicher, politischer, regulatorischer oder klinischer Ergebnisse oder Praktiken, Verhaltensmuster oder Praktiken von Kunden und verschreibenden Ärzten, Erstattungsaktivitäten und -ergebnissen, Auswirkungen von Pandemien oder anderen weit verbreiteten Gesundheitsproblemen auf unser Geschäft, Ergebnisse, Fortschritte sowie anderer solcher Schätzungen und Ergebnisse. Zukunftsgerichtete Aussagen sind mit erheblichen Risiken und Unsicherheiten verbunden, einschließlich der nachstehend erläuterten Risiken und der Risiken, die ausführlicher in den von Amgen bei der Securities and Exchange Commission eingereichten Berichten beschrieben sind, darunter unser jüngster Jahresbericht auf Form 10-K sowie alle nachfolgenden regelmäßigen Berichte auf Form 10-Q und aktuellen Berichte auf Form 8-K. Sofern nicht anders angegeben, stellt Amgen diese Informationen zum Datum dieser Pressemitteilung zur Verfügung und übernimmt keine Verpflichtung, die in diesem Dokument enthaltenen zukunftsgerichteten Aussagen aufgrund neuer Informationen, zukünftiger Ereignisse oder aus anderen Gründen zu aktualisieren.

Keine zukunftsgerichtete Aussage kann garantiert werden, und die tatsächlichen Ergebnisse können erheblich von denen abweichen, die wir prognostizieren. Die Entdeckung oder Identifizierung neuer Produktkandidaten oder die Entwicklung neuer Indikationen für bestehende Produkte kann nicht garantiert werden und der Weg vom Konzept zum Produkt ist ungewiss. Folglich kann nicht garantiert werden, dass ein bestimmter Produktkandidat oder die Entwicklung einer neuen Indikation für ein bestehendes Produkt erfolgreich sein und zu einem kommerziellen Produkt werden wird. Außerdem sind die präklinischen Ergebnisse keine Garantie für die sichere und wirksame Leistung der Produktkandidaten beim Menschen. Die Komplexität des menschlichen Körpers kann durch Computer- oder Zellkultursysteme oder Tiermodelle nicht perfekt oder manchmal nicht einmal adäquat modelliert werden. Die Zeit, die wir benötigen, um klinische Studien abzuschließen und die behördliche Genehmigung für die Produktvermarktung zu erhalten, war in der Vergangenheit unterschiedlich lang, und wir erwarten ähnliche Schwankungen in der Zukunft. Selbst wenn die klinischen Studien erfolgreich verlaufen, können die Zulassungsbehörden die von uns gewählten Studienendpunkte als ausreichend für die Zulassung anzweifeln. Wir entwickeln Produktkandidaten sowohl intern als auch im Rahmen von Lizenzkooperationen, Partnerschaften und Joint Ventures. Produktkandidaten, die aus Beziehungen abgeleitet werden, können Gegenstand von Streitigkeiten zwischen den Parteien sein oder sich als weniger wirksam oder sicher erweisen, als wir zum Zeitpunkt des Eingehens einer solchen Beziehung angenommen haben. Außerdem könnten wir oder andere Sicherheits-, Nebenwirkungs- oder Herstellungsprobleme mit unseren Produkten, einschließlich unserer Geräte, feststellen, nachdem sie auf dem Markt sind.

Unsere Ergebnisse können von unserer Fähigkeit beeinflusst werden, neue und bestehende Produkte im In- und Ausland erfolgreich zu vermarkten, von klinischen und regulatorischen Entwicklungen bei aktuellen und zukünftigen Produkten, vom Umsatzwachstum kürzlich eingeführter Produkte, von der Konkurrenz durch andere Produkte, einschließlich Biosimilars, von Schwierigkeiten oder Verzögerungen bei der Herstellung unserer Produkte und von den globalen wirtschaftlichen Bedingungen, einschließlich derjenigen, die sich aus geopolitischen Beziehungen und Regierungsmaßnahmen ergeben. Darüber hinaus wird der Absatz unserer Produkte durch Preisdruck, politische und öffentliche Kontrolle sowie durch die Erstattungsrichtlinien von Drittanbietern, einschließlich Regierungen, privaten Versicherungsplänen und Managed-Care-Anbietern, beeinflusst. Er kann auch durch regulatorische, klinische und richtlinienbezogene Entwicklungen sowie durch nationale und internationale Trends in Richtung Managed Care und Kostendämpfung im Gesundheitswesen beeinflusst werden. Darüber hinaus unterliegen unsere Forschungs-, Test-, Preisgestaltungs-, Vermarktungs- sowie sonstigen Tätigkeiten einer umfassenden Regulierung durch in- und ausländische staatliche Aufsichtsbehörden. Unser Geschäft könnte durch staatliche Ermittlungen, Rechtsstreitigkeiten sowie Produkthaftungsansprüche beeinträchtigt werden. Zusätzlich könnte unser Geschäft durch die Einführung neuer Steuergesetze oder durch zusätzliche Steuerschulden beeinträchtigt werden. Weiterhin könnte der Schutz, den unsere Patente und Patentanmeldungen bieten, obwohl wir routinemäßig Patente für unsere Produkte und Technologien erhalten, von unseren Wettbewerbern angefochten, für ungültig erklärt oder umgangen werden, oder wir könnten in gegenwärtigen und künftigen Rechtsstreitigkeiten im Bereich geistiges Eigentum keinen Erfolg haben. Wir führen einen erheblichen Teil unserer kommerziellen Herstellungstätigkeiten in wenigen zentralen Einrichtungen durch, unter anderem in Puerto Rico, und sind zudem für einen Teil unserer Herstellungstätigkeiten auf Dritte angewiesen, und Lieferbeschränkungen könnten den Absatz bestimmter unserer derzeitigen Produkte sowie die Entwicklung bestimmter unserer Produktkandidaten einschränken. Der Ausbruch einer Krankheit oder eine ähnliche Bedrohung der öffentlichen Gesundheit sowie die öffentlichen und staatlichen Bemühungen, die Ausbreitung einer solchen Krankheit einzudämmen, könnten erhebliche nachteilige Auswirkungen auf die Versorgung mit Materialien für unsere Herstellungstätigkeiten, die Distribution unserer Produkte, die Vermarktung unserer Produktkandidaten sowie den Betrieb unserer klinischen Studien haben, und derartige Ereignisse könnten einen wesentlichen nachteiligen Einfluss auf unsere Produktentwicklung, unseren Produktabsatz, unser Geschäft sowie unsere Betriebsergebnisse haben. Wir sind bei der Entwicklung einiger unserer Produktkandidaten sowie bei der Vermarktung und dem Verkauf einiger unserer kommerziellen Produkte auf Kooperationen mit Dritten angewiesen. Zusätzlich stehen wir im Wettbewerb mit anderen Unternehmen, sowohl in Bezug auf viele unserer vermarkteten Produkte als auch bei der Entdeckung und Entwicklung neuer Produkte. Außerdem werden einige Rohstoffe, medizinische Geräte und Bauteile für unsere Produkte ausschließlich von Drittanbietern geliefert. Einige unserer Vertriebspartner, Kunden und Kostenträger haben in ihren Geschäftsbeziehungen mit uns eine erhebliche Kaufkraft. Die Entdeckung signifikanter Probleme mit einem Produkt, das einem unserer Produkte ähnlich ist und eine ganze Produktklasse betrifft, könnte erhebliche negative Auswirkungen auf den Absatz der betroffenen Produkte sowie auf unsere Geschäfts- und Betriebsergebnisse haben. Unsere Bemühungen, mit anderen Unternehmen, Produkten oder Technologien zusammenzuarbeiten oder diese zu erwerben, sowie die Geschäftsabläufe solcher Unternehmen zu integrieren oder die von uns erworbenen Produkte oder Technologien zu unterstützen, könnten nicht erfolgreich sein und könnten zu unerwarteten Kosten, Verzögerungen oder dazu führen, dass die Vorteile der Transaktionen nicht realisiert werden. Ein Ausfall, ein Cyberangriff oder eine Verletzung der Informationssicherheit unserer IT-Systeme könnte die Vertraulichkeit, Integrität und Verfügbarkeit unserer Systeme und Daten gefährden. Unser Aktienkurs ist volatil und kann durch eine Reihe von Ereignissen beeinflusst werden. Unser Geschäft und unsere Aktivitäten könnten durch das Scheitern oder das vermeintliche Scheitern bei der Erreichung unserer Nachhaltigkeitsziele negativ beeinflusst werden. Die Auswirkungen des globalen Klimawandels und der damit verbundenen Naturkatastrophen könnten sich negativ auf unser Geschäft und unseren Betrieb auswirken. Die globale Wirtschaftslage kann bestimmte Risiken, die unser Geschäft beeinträchtigen, verstärken. Unsere Geschäftsentwicklung könnte die Fähigkeit unseres Verwaltungsrats beeinträchtigen oder einschränken, eine Dividende zu beschließen, oder unsere Fähigkeit beeinträchtigen, eine Dividende zu zahlen oder unsere Stammaktien zurückzukaufen. Wir könnten nicht in der Lage sein, Zugang zu den Kapital- und Kreditmärkten zu für uns günstigen Bedingungen oder überhaupt zu erhalten.

KONTAKT: Amgen, Thousand Oaks
Madison Howard, 773-636-4910 (Medien)
Elissa Snook, 609-251-1407 (Medien)
Casey Capparelli, 805-447-1746 (Investoren)

LITERATURVERZEICHNIS

Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., Commodore-Mensah, Y., Currie, M. E., Elkind, M. S. V., Fan, W., Generoso, G., Gibbs, B. B., Heard, D. G., Hiremath, S., Johansen, M. C., & Kazi, D. S. (2025). 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation, 151(8). https://doi.org/10.1161/cir.0000000000001303. MAC: REF-107092 Le, H. et al. (2025). Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease. JACC, Volume 86 (Number 14) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455. Eroglu T, Capone F, Schiattarella GG. The evolving landscape of cardiometabolic diseases. EBioMedicine. 2024 Nov;109:105447. doi: 10.1016/j.ebiom.2024.105447. Online veröffentlicht am 4. November 2024. PMID: 39500010; PMCID: PMC11570325.  Tan SH, Wu JL, Zhuo SX, Zhang Y, Wang M. Residual risk in atherosclerotic cardiovascular disease after statin therapy: Clinical mechanisms and management strategies. World J Cardiol. 26. Februar 2026; 18(2):114960. doi: 10.4330/wjc.v18.i2.114960. PMID: 41694036; PMCID: PMC12897005. Data on File. Amgen, 2025. Data on File. Amgen, 2025. Ndumele, C. E., & Blumenthal, R. S. (2025). VESALIUS and the Anatomy of High-Risk Prevention. New England Journal of Medicine. https://doi.org/10.1056/nejme2515447 Marston, N. A., Bohula, E. A., Bhatia, A. K., et al. (2026). Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes: Results from the VESALIUS‑CV trial. JAMA. https://doi.org/10.1001/jama.2026.3277 Data on File. Amgen, 2026. Data on File. Amgen, 2025.

Regeneron Pharmaceuticals, Inc. (REGN) Q2 2026 Earnings Call July 30, 2026 8:30 AM EDT

Company Participants

Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis
Leonard Schleifer - Co-Founder, President, CEO & Co-Chairman
George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman
Marion McCourt - Executive Vice President of Commercial
Christopher Fenimore - Executive VP of Finance & CFO

Conference Call Participants

Christopher Raymond - Raymond James & Associates, Inc., Research Division
Taylor Hanley - JPMorgan Chase & Co, Research Division
Tyler Van Buren - TD Cowen, Research Division
Mario Joshua Chazaro Cortes - Evercore ISI Institutional Equities, Research Division
Salveen Richter - Goldman Sachs Group, Inc., Research Division
Alexandria Hammond - Wolfe Research, LLC
Tazeen Ahmad - BofA Securities, Research Division
Evan Seigerman - BMO Capital Markets Equity Research
Gregory Renza - Truist Securities, Inc., Research Division
Carter Gould - Cantor Fitzgerald & Co., Research Division
Geoffrey Meacham - Citigroup Inc., Research Division

Presentation

Operator

Welcome to the Regeneron Pharmaceuticals Second Quarter 2026 Earnings Conference Call. My name is Michelle, and I'll be your operator for today's call. [Operator Instructions] Please note that this conference call is being recorded.

I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin.

Ryan Crowe
Senior Vice President of Investor Relations & Strategic Analysis

Thank you, Michelle. Good morning, good afternoon, and good evening to everyone listening around the world. Thank you for your interest in Regeneron, and welcome to our second quarter 2026 earnings conference call. An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after our call concludes.

Joining me on today's call are Dr. Leonard Schleifer, Co-Founder, Board, Co-Chair, President and Chief Executive Officer; Dr. George Yancopoulos, Co-Founder, Board, Co-Chair, President and Chief Scientific Officer; Marion McCourt, Executive Vice President, Commercial; and Chris Fenimore, Executive Vice President, Finance and Chief Financial Officer.

The Coinbase logo is seen in this illustration created on November 3, 2025. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

CompaniesNEW YORK, July 30 (Reuters) - Coinbase (COIN.O), opens new tab won the dismissal on Thursday of much of a lawsuit in which customers accused the largest U.S. cryptocurrency exchange of ​illegally selling securities without registering as an exchange or broker-dealer.

Customers sued ‌over 60 tokens, including XRP and dogecoin, that they claimed were unregistered securities, seeking unspecified damages in the proposed class action.

The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.

U.S. District Judge Paul Engelmayer in Manhattan dismissed all claims based ​on "matched" transactions where Coinbase paired customers' buy and sell orders. These accounted ​for an estimated 99.97% of trading volume, equal to hundreds of ⁠billions of dollars.

The judge also said customers may pursue claims over "inventory" transactions, where ​Coinbase fills orders from tokens it owns. These accounted for the remaining trading volume, ​comprising at least $178 million in sales.

Lawyers for the customers did not immediately respond to requests for comment. Coinbase and its lawyers did not immediately respond to similar requests.

Like other cryptocurrency industry ​participants, Coinbase has seen a rollback of regulatory oversight under the second Trump ​administration.

The lawsuit's outcome turned on whether Coinbase qualified as a statutory seller under the federal Securities ‌Act ⁠of 1933 and state "blue sky" laws designed to prevent fraudulent securities sales.

Engelmayer said Coinbase was not a statutory seller for matched transactions because it did not pass ownership of tokens to buyers, and did not induce, or "solicit," the transactions merely by ​providing basic overviews of ​tokens and their ⁠price histories.

Coinbase was a statutory seller for inventory transactions, however, because it passed title of tokens to buyers, and acted ​as a dealer and underwriter, Engelmayer said.

The lawsuit began in ​2021. Engelmayer dismissed ⁠other federal securities law claims in 2023.

Digital Chamber, a cryptocurrency trade group, supported Coinbase, saying an expansive definition of statutory seller could stifle innovation and drive trading volume ⁠to non-U.S. ​exchanges.

Last year, the U.S. Securities and Exchange Commission ended ​a lawsuit it brought in 2023 that accused Coinbase of allowing trading in tokens that should have ​been registered as securities.

Reporting by Jonathan Stempel in New York; Editing by Joe Bavier

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Crocs, Inc. (NASDAQ:CROX) shares fell almost 10% on Thursday after the footwear company issued a weaker-than-expected third quarter outlook, as tariff pressures and continued weakness at its HEYDUDE brand weighed on sentiment, despite a second-quarter earnings and revenue beat.

The company forecast Q3 adjusted earnings per share of $3.20 to $3.30 on roughly flat revenue, below Wall Street expectations for adjusted EPS of around $3.53 to $3.55 and revenue of about $1 billion. Crocs attributed the outlook to ongoing tariff impacts and product mix pressures.

For the second quarter of 2026, Crocs reported adjusted earnings per share of $4.55, above analyst estimates of $4.32 to $4.35.

Revenue came in at $1.18 billion, topping expectations of $1.15 billion and rising 2.6% from the prior year.

The company’s core Crocs brand surpassed $1 billion in quarterly revenue for the first time, with sales increasing 4.3% year over year to $1 billion. Direct-to-consumer revenue for the brand rose 12.9%, while wholesale revenue declined 5%.

HEYDUDE continued to face challenges, with quarterly revenue falling 5.7% to $179 million. Direct-to-consumer sales increased 7.2%, but wholesale revenue declined 17.2%.

Overall gross margin declined to 59.4% from 61.7% a year earlier, while adjusted gross margin fell 170 basis points to 60% as tariff-related costs affected profitability. Adjusted operating income declined 4.5% to $296 million, with adjusted operating margin narrowing to 25.1% from 26.9%.

Crocs raised its full-year 2026 outlook, now expecting revenue growth of approximately 1% to 2%, compared with its previous forecast of down 1% to up 1%. Adjusted diluted earnings per share guidance was increased to a range of $13.70 to $14, up from the prior range of $13.20 to $13.75.

“Our results reflect broad consumer demand across both brands, healthy direct-to-consumer growth, and strong consumer response to new product innovation,” Crocs CEO Andrew Rees said in a statement.  

The company also announced that its board increased its share repurchase authorization by $1.5 billion, leaving approximately $2 billion available for future buybacks. During the quarter, Crocs repurchased about 2.3 million shares for $251 million.

Yum China Holdings, Inc. (YUMC) Q2 2026 Earnings Call July 30, 2026 7:00 AM EDT

Company Participants

Florence Lip - Senior Director of Investor Relations
Joey Wat - CEO & Executive Director
Adrian Ding - Chief Financial Officer

Conference Call Participants

Michelle Cheng - Goldman Sachs Group, Inc., Research Division
Chen Luo - BofA Securities, Research Division
Lillian Lou - Morgan Stanley, Research Division
Kin Shun Ling - Jefferies LLC, Research Division
Xiaopo Wei - Citigroup Inc. Exchange Research
Christine Peng - UBS Investment Bank, Research Division
Yushen Wang - CLSA Limited, Research Division

Presentation

Operator

Good day, everyone, and thank you for standing by. Welcome to Yum China's Second Quarter 2026 Earnings Conference Call.

[Operator Instructions]

Please be advised that today's conference is being recorded. Now it's my pleasure to hand the conference to Florence Lip, Senior Director of Investor Relations. Please proceed.

Florence Lip
Senior Director of Investor Relations

Thank you, operator. Hello, everyone, and welcome to Yum China's Second Quarter 2026 Earnings Conference Call. With me on the call are our CEO, Ms. Joey Wat; and our CFO, Mr. Adrian Ding. Before we begin, I will remind everyone that our remarks and investor materials contain forward-looking statements. These are subject to future events and uncertainties, and actual results may differ materially.

Please refer to these forward-looking statements together with the cautionary statement in our earnings release and the risk factors included in our SEC filings. We'll also be talking about non-GAAP financial measures. We encourage you to review the comparable GAAP measures, along with the reconciliation of non-GAAP and GAAP measures provided in our earnings release, which is available on our Investor Relations website at ir.yumchina.com.

You can also find both the webcast replay and a PowerPoint presentation on our IR website. Please note that all year-over-year growth rates discussed today exclude the impact

Flowserve Corporation (FLS) Q2 2026 Earnings Call July 30, 2026 8:30 AM EDT

Company Participants

Brian Ezzell - Treasurer and VP of Investor Relations & Corporate Finance
Robert Rowe - President, CEO & Director
Amy Schwetz - Senior VP, CFO & Interim Principal Accounting Officer

Conference Call Participants

Andrew Kaplowitz - Citigroup Inc., Research Division
Deane Dray - RBC Capital Markets, Research Division
Michael Halloran - Robert W. Baird & Co. Incorporated, Research Division
Adam Farley - Stifel, Nicolaus & Company, Incorporated, Research Division
Amit Mehrotra - UBS Investment Bank, Research Division
Christopher Grenga - TD Cowen, Research Division
Andrew Obin - BofA Securities, Research Division

Presentation

Operator

Good day, everyone, and welcome to the Flowserve Second Quarter 2026 Earnings Call. Today's conference is being recorded.

At this time, I would like to turn the conference over to Mr. Brian Ezzell, Vice President of Investor Relations. Please go ahead, sir.

Brian Ezzell
Treasurer and VP of Investor Relations & Corporate Finance

Thank you, and good morning, everyone. Welcome to Flowserve's Second Quarter 2026 Business Update. I'm joined by Scott Rowe, Flowserve's President and Chief Executive Officer; and Flowserve Chief Financial Officer, Amy Schwetz. Following Scott, and Amy's prepared remarks, we'll open the call for questions.

Turning to Slide 2. Our discussion will contain forward-looking statements that are based upon information available as of today. Actual results may differ due to risks and uncertainties. Refer to additional information, including our note on non-GAAP measures in our press release, earnings presentation and SEC filings, which are available on our website.

With that, I will turn it over to Scott.

Robert Rowe
President, CEO & Director

Thank you, Brian, and good morning, everyone. Turning to Slide 3. I'd like to begin by thanking our associates around the world for their hard work, disciplined execution and resilience in what remains a dynamic environment. The second quarter was

SummaryCompaniesAmeren projects winter 2032 capacity shortfall of about 1,500 MW after plant startupShortfall grows to about 2,300 MW in 2033, Ameren estimatesRegulatory process starts with August 20 prehearing conference before Missouri Public Service CommissionJuly 30 (Reuters) - Ameren's planned mega gas plant for the Midwest will still leave the utility ‌short of the power and reserves needed to meet surging data center demand, the company's own analysis showed ahead of a key approval process next month.

The projected shortfall highlights mounting strain on U.S. power grids as data center demand grows faster ​than the generation and transmission capacity needed to support it.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

St. Louis-based Ameren's urgency for the project ​is acute after signing contracts this year to provide electricity to data centers in ⁠development by Amazon (AMZN.O), opens new tab and Alphabet's Google (GOOGL.O), opens new tab in rural Missouri.

Ameren (AEE.N), opens new tab says the 2,100-megawatt West Alton Energy Center is ​necessary, but would not fully restore the reserve cushion needed to meet projected demand. The project is planned for ​a site next to a coal plant on the banks of the Mississippi River about 28 miles (45 km) northwest of St. Louis.

"The company's resource capacity still falls well short of the total demand" and planned reserve margin, Ameren Director of Corporate ​Analysis Matt Michels said in July 24 testimony filed with the Missouri Public Service Commission.

An August 20 ​prehearing conference will kick off the regulatory process for Ameren to obtain approval to construct the power plant.

Ameren estimates the ‌plant would ⁠come online in late 2031. But Ameren's capacity shortfall in the winter of 2032, for example, would equal about 1,500 MW and grow to about 2,300 MW the following year, Michels said in his testimony.

Ameren executives say the utility also will build capacity by enhancing existing power sources, developing solar and battery energy storage ​sites and purchasing power from ​the regional grid.

Ameren's service ⁠area falls within the Midcontinent ISO, which manages the flow of electricity for a territory that includes all or part of 15 U.S. states in the Midwest ​and South.

The total return on Ameren's stock over the past 12 months is ​12.7%, outpacing ⁠the 8.4% for the S&P 500 Utilities Sector (.SPLRCU), opens new tab, as investors anticipate strong earnings growth over the next decade.

"Ameren anticipates more than $70 billion of additional investment opportunities over the next 10 years, providing a long runway of growth," Morningstar ⁠analyst Andrew ​Bischof wrote this week in a research note.

"The most attractive ​opportunities are supporting data center development in Illinois and Missouri, new generation in Missouri, modernizing the grid in Illinois and Missouri, and transmission ​expansion across the Midcontinent electric grid," Bischof said.

Reporting By Tim McLaughlin; editing by Timothy Gardner and Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles., opens new tab